Teligent (TLGTQ) 10-Q 12 Dec 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Dec. 10, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	Teligent, Inc.
Entity Central Index Key	352,998
Document Period End Date	Sep. 30, 2018
Entity Filer Category	Accelerated Filer
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2,018
Document Type	10-Q
Amendment Flag	false
Trading Symbol	TLGT
Entity Common Stock, Shares Outstanding		53,774,221

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 15,267	$ 26,692
Accounts receivable, net of allowance for doubtful accounts of $2,787 and $2,185, as of September 30, 2018 and December 31, 2017, respectively	16,707	12,742
Inventories, net	17,882	16,075
Prepaid expenses and other receivables	1,522	3,622
Total current assets	51,378	59,131
Property, plant and equipment, net	88,387	68,355
Intangible assets, net	52,045	56,017
Goodwill	464	471
Other assets	608	611
Total assets	192,882	184,585
Current liabilities:
Accounts payable	4,476	10,595
Accrued expenses	10,437	8,101
2021 Term Loan, net of debt discount and debt issuance costs (face of $25,000 as of September 30, 2018)	24,168	0
Total current liabilities	39,081	18,696
Convertible 3.75% Senior Notes, net of debt discount and debt issuance costs (face of $68,660 and $143,750 as of September 30, 2018 and December 31, 2017, respectively)	61,634	120,977
Convertible 4.75% Senior Notes, net of debt discount and debt issuance costs (face of $75,090 as of September 30, 2018)	56,148	0
Deferred tax liability	249	159
Other long term liabilities	70	0
Total liabilities	157,182	139,832
Commitments and Contingencies
Stockholders’ equity:
Common stock, $0.01 par value, 100,000,000 shares authorized; 53,762,888 and 53,400,281 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively	557	554
Additional paid-in capital	119,346	106,312
Accumulated deficit	(81,960)	(60,094)
Accumulated other comprehensive loss	(2,243)	(2,019)
Total stockholders’ equity	35,700	44,753
Total liabilities and stockholders' equity	$ 192,882	$ 184,585

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounts receivable, net of allowance for doubtful debt	$ 2,787,000	$ 2,185,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	53,762,888	53,400,281
Common stock, shares outstanding (in shares)	53,762,888	53,400,281
Term Loan 2021
Face amount of the Notes	$ 25,000,000
Convertible Note 2019
Stated interest rate	3.75%	3.75%
Face amount of the Notes	$ 68,660,000	$ 143,750,000
Convertible Note 2023
Stated interest rate	4.75%	4.75%
Face amount of the Notes	$ 75,090,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Revenue, net	$ 18,294	$ 11,340	$ 49,088	$ 45,435
Costs and expenses:
Cost of revenues	11,575	8,802	32,365	23,926
Selling, general and administrative expenses	4,845	5,971	15,932	14,976
Product development and research expenses	3,087	4,606	10,445	13,387
Total costs and expenses	19,507	19,379	58,742	52,289
Operating loss	(1,213)	(8,039)	(9,654)	(6,854)
Other Income (Expense):
Foreign currency exchange (loss) gain	(176)	1,744	(2,071)	6,645
Partial extinguishment of Convertible 3.75% Senior Notes	0	0	(2,467)	0
Interest and other expense, net	(2,693)	(2,663)	(7,764)	(8,731)
Income tax (benefit) expense	(137)	24	(90)	130
Loss before income tax expense	(4,082)	(8,958)	(21,956)	(8,940)
Net loss	$ (3,945)	$ (8,982)	$ (21,866)	$ (9,070)
Basic and diluted loss per share (in dollars per share)	$ (0.07)	$ (0.17)	$ (0.41)	$ (0.17)
Weighted average shares of common stock outstanding:
Basic and diluted shares (in shares)	53,625,768	53,391,948	53,532,277	53,297,889

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENSTS OF OPERATIONS (Parenthetical)	Sep. 30, 2018	Dec. 31, 2017
Convertible Note 2019
Stated interest rate	3.75%	3.75%

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Net loss	$ (3,945)	$ (8,982)	$ (21,866)	$ (9,070)
Other comprehensive income (loss), net of tax;
Foreign currency translation adjustment	108	378	(224)	133
Other comprehensive income (loss)	108	378	(224)	133
Comprehensive loss	$ (3,837)	$ (8,604)	$ (22,090)	$ (8,937)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2018 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Convertible Note 2023	Convertible Note 2023Additional Paid-in Capital	Convertible Note 2019	Convertible Note 2019Additional Paid-in Capital
Balance (in shares) at Dec. 31, 2017		53,400,281
Balance at Dec. 31, 2017	$ 44,753	$ 554	$ 106,312	$ (2,019)	$ (60,094)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation expense	1,654		1,654
Stock options exercised (in shares)		236,000
Stock options exercised	246	$ 2	244
Issuance of stock for vested restricted stock units (in shares)		101,607
Issuance of stock for vested restricted stock units		$ 1	(1)
Issuance of stock to consultant (in shares)		25,000
Issuance of stock to consultant	102		102
Fair value of conversion feature on Convertible 4.75% Senior Notes						$ 18,637	$ 18,637
Partial extinguishment of equity component of Convertible 3.75% Senior Notes	7,600							$ (7,602)	$ (7,602)
Cumulative translation adjustment	(224)			(224)
Net loss	(21,866)				(21,866)
Balance (in shares) at Sep. 30, 2018		53,762,888
Balance at Sep. 30, 2018	$ 35,700	$ 557	$ 119,346	$ (2,243)	$ (81,960)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)	Sep. 30, 2018	Dec. 31, 2017
Convertible Note 2023
Stated interest rate	4.75%	4.75%
Convertible Note 2019
Stated interest rate	3.75%	3.75%

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (21,866)	$ (9,070)
Reconciliation of net loss to net cash used in operating activities
Depreciation and amortization of fixed assets	1,703	1,264
Provision for bad debt expense	601	1,738
Provision for write down of inventory	844	1,489
Issuance of stock to consulant	102	0
Stock based compensation	1,572	2,427
Amortization of debt issuance costs	727	695
Amortization of intangible assets	2,302	2,143
Foreign currency exchange loss (gain)	2,071	(6,645)
Partial extinguishment of Convertible 3.75% Senior Notes	2,467	0
Amortization of debt discount	6,353	6,376
Gain on sale of fixed assets	(20)	0
Loss on impairment of intangible assets	22	113
Changes in operating assets and liabilities
Accounts receivable	(4,587)	(2,491)
Inventories	(2,746)	(2,767)
Prepaid expenses and other current receivables	2,081	510
Other assets	4	21
Accounts payable and accrued expenses	(6,944)	1,537
Net cash used in operating activities	(15,314)	(2,660)
Cash flows from investing activities:
Capital expenditures	(18,315)	(26,002)
Proceeds from sale of fixed assets	38	0
Net cash used in investing activities	(18,277)	(26,002)
Cash flows from financing activities:
Proceeds from exercise of common stock options	246	269
Proceeds from 2021 Term Loan	25,000	0
Debt fees on Convertible 4.75% Senior Notes and 2021 Term Loan	(2,539)	0
Net cash provided by financing activities	22,707	269
Effect of exchange rate on cash and cash equivalents	(542)	618
Net decrease in cash, cash equivalents and restricted cash	(10,884)	(28,393)
Cash, cash equivalents and restricted cash at beginning of period	27,165	66,481
Cash, cash equivalents and restricted cash at end of period	15,739	38,706
Supplemental Cash flow information:
Cash payments for interest	3,136	2,695
Cash payments for income taxes	66	102
Non-cash operating, investing and financing transactions:
Acquisition of capital expenditures in accounts payable and accrued expenses	1,316	5,029
Issuance of stock to a consultant	102	0
Capitalized interest in capital expenditures	2,013	1,058
Capitalized stock compensation in capital expenditures	$ 82	$ 101

CONDENSED CONSOLIDATED STATEM_7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - Senior Notes	Sep. 30, 2018	Sep. 30, 2017
3.75% Senior Note
Stated interest rate	3.75%	3.75%
4.75% Senior Note
Stated interest rate	4.75%	4.75%

Correction to Previously Issued

Correction to Previously Issued Unaudited Interim Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2018
Accounting Changes and Error Corrections [Abstract]
Correction to Previously Issued Unaudited Interim Condensed Consolidated Financial Statements	1. Correction to Previously Issued Unaud ited Interim Condensed Consolidated Financial Statements Subsequent to the issuance of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, management determined adjustments were needed to correct the presentation of certain errors in the Company’s previously reported unaudited condensed consolidated financial statements as of and for the three and nine-months ended September 30, 2017. Accordingly, the accompanying Condensed Consolidated Statement of Operations of the Company for the three and nine-months ended September 30, 2017, and the related notes hereto, have been revised to correct these errors (the “Revision”). A summary of the correction of these errors, and their impact on the accompanying Condensed Consolidated Statement of Operations for the three and nine-months ended September 30, 2017 are, as follows: (1) The Company pays wholesalers certain fees associated with the sale of the Company's product. The payment of these fees had been historically classified by the Company as cost of revenues and accrued expenses prior to the adoption of ASC 606, Revenue from Contracts with Customers. As disclosed in Note 4, the Company adopted ASC 606 on January 1, 2018 using the modified retrospective method, at which time the Company began classifying the payment of wholesaler fees as a reduction of revenue and accounts receivable. Upon further analysis, however, management determined that these fees should have always been classified as a reduction of revenue and accounts receivable, rather than as costs of revenues and accrued expenses, because the services provided by the Company’s wholesalers cannot generally be provided by third parties and the underlying fees are not specifically identifiable from other services. As a result, the accompanying Condensed Consolidated Statement of Operations for the three and nine-months ended September 30, 2017 has been revised to correct the presentation of wholesaler fees as a reduction of revenue rather than as cost of revenues. The correction of this error resulted in a reduction of revenue of approximately $1.5 million and $5.7 million, respectively, for the three and nine-month periods ended September 30, 2017. In addition, the correction of this error resulted in a reduction in accounts receivable and decrease in accrued expenses of approximately $6.1 million, respectively, as of September 30, 2017 and $7.0 million, respectively, as of December 31, 2017. (2) Prior to the adoption of ASC 606, the Company classified Medicaid, Medicare and other rebates (the "Rebates") as a reduction of accounts receivable, whereas subsequent to adoption of ASC 606 the Company began classifying the Rebates as accrued expenses. Upon further analysis, management determined that the Rebates should have always been classified as accrued expenses because their terms require cash settlement and are payable to third parties that are other than the Company's customer. The correction of this error resulted in an increase in accounts receivable and increase in accrued expenses of $2.3 million, respectively, as of September 30, 2017 and $1.6 million, respectively, as of December 31, 2017. The following tables summarize the effects of the Revision on the Company's unaudited interim condensed consolidated financial statements as of and for the three and nine-months ended September 30, 2017 (in thousands): Condensed Consolidated Statements of Operations Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 As Previously As Previously Reported Adjustment As Revised Reported Adjustment As Revised Revenue, net 12,851 1,511 (1) 11,340 51,150 5,715 (1) 45,435 Cost of revenues 10,313 1,511 (1) 8,802 29,641 5,715 (1) 23,926 Total costs and expenses 20,890 1,511 (1) 19,379 58,004 5,715 (1) 52,289 Condensed Consolidated Balance Sheet Condensed Consolidated Balance Sheet September 30, 2017 December 31, 2017 As Previously As Previously Reported Adjustment As Revised Reported Adjustment As Revised Accounts receivable, net 25,026 3,800 (1),(2) 21,226 18,143 5,401 (1),(2) 12,742 Total current assets 79,846 3,800 (1),(2) 76,046 64,532 5,401 (1),(2) 59,131 Total assets 194,466 3,800 (1),(2) 190,666 189,986 5,401 (1),(2) 184,585 Accrued expenses 16,372 3,800 (1),(2) 12,572 13,502 5,401 (1),(2) 8,101 Total current liabilities 25,237 3,800 (1),(2) 21,437 24,097 5,401 (1),(2) 18,696 Total liabilities 143,939 3,800 (1),(2) 140,139 145,233 5,401 (1),(2) 139,832 Total liabilities and stockholders' equity 194,466 3,800 (1),(2) 190,666 189,986 5,401 (1),(2) 184,585 Condensed Consolidated Statement of Cash Flows Nine Months Ended September 30, 2017 As Previously Reported Adjustment As Revised Cash flows from operating activities Accounts receivable (4,960) (2,469) (1),(2) (2,491) Accounts payable and accrued expenses 4,006 2,469 (1),(2) 1,537

Nature of the Business and Liqu

Nature of the Business and Liquidity	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Liquidity	Nature of the Business and Liquidity Nature of the Business Teligent, Inc. and its subsidiaries (collectively the “Company”), is a specialty generic pharmaceutical company. Our mission is to become a leader in the specialty generic pharmaceutical market in alternate dosage forms. Under our own label, we currently market and sell generic topical and generic and branded generic injectable pharmaceutical products in the United States and Canada. In the United States, we currently market 32 generic topical pharmaceutical products and four branded generic injectable pharmaceutical products. In Canada, we sell over 30 generic and branded generic injectable products and medical devices. Generic pharmaceutical products are bioequivalent to their brand name counterparts. We also provide contract manufacturing services to the pharmaceutical, over-the-counter ("OTC"), and cosmetic markets. We operate our business under one reportable segment. Our common stock is traded on the NASDAQ Global Select Market under the trading symbol “TLGT.” Our principal executive office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. We have additional offices located in Iselin, New Jersey, Toronto, Canada, and Tallinn, Estonia. Liquidity Our capital resources were comprised of cash and cash equivalents of $15.3 million and $26.7 million as of September 30, 2018 and December 31, 2017, respectively. The reduction in our cash during the nine months ended September 30, 2018 was largely due to our additional year-to-date investment of $18.3 million in the Company's new manufacturing facility located in Buena, New Jersey, along with the timing of our accounts receivable collections and expense payments associated with our launch of six new products in the U.S. market. In addition, we had an accumulated deficit of $82.0 million as of September 30, 2018, and incurred a $21.9 million net loss and used $15.3 million in net cash from operating activities during the nine months ended September 30, 2018. Our liquidity needs have typically arisen from the funding of our new manufacturing facility, product manufacturing costs, research and development programs and the launch of new products. In the past, we have met these cash requirements through cash inflows from operations, working capital management, and proceeds from borrowings such as our Convertible Senior Notes and Term Loan discussed in Note 7. We expect to continue to incur significant expenditures for the development of new products in our pipeline, and the manufacturing and sales and marketing of our existing product. While we rely heavily on cash flows from operating activities and borrowings from outside sources to execute our operational strategy and meet our financial commitments and other short-term financial needs, we cannot be certain that sufficient capital will be generated through operations or will be available to the Company to the extent required and on acceptable terms. In addition, were unable to file our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 with the SEC by the required filing date. As a result, the Company was not in compliance with a non-financial covenant prescribed by our Term Loan, which requires timely filing of our annual and interim consolidated financial statements, and our ability to offer up to $50.0 million in debt or equity securities through our existing shelf registration statement on file with the SEC was suspended for a period of twelve months. Moreover, due to the lack of compliance with the non-financial covenant prescribed by our Term Loan, we reclassified the net carrying value of $24.2 million as current debt in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. The foregoing matters, when considered in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern. However, the accompanying Condensed Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. Notwithstanding these matters, we continue to implement various actions, which we believe are probable of occurring and, as such, alleviate substantial doubt about the Company’s ability to continue as a going concern. A summary of these actions are as follows: • We ar e closely managing our recurring operating expenses and limiting our non-recurring operating expenses over the next twelve-month period. • We have completed the con struction of our manufacturing facility in Buena, New Jersey and are limiting cash outflows for other capital expenditures. Moreover, we have the ability to delay other capital projects until such time that our liquidity improves, or we receive funding from outside sources. • O n November 12, 2018, the Company entered into a financing commitment whereby Ares Capital Management ("Ares") has agreed to loan the Company up to $120.0 million ("Ares Credit Facility"). The Ares Credit Facility will be secured by all of the Company's assets and will be funded in three tranches: (1) an asset based revolving credit facility of $25.0 million due November 2022 ("2022 Revolver"), (2) a term loan of $80.0 million due February 2023 ("2023 Term Loan"), and (3) a delayed draw term loan of $15.0 million also due in February 2023 ("2023 Delayed Draw Term Loan"). In addition, the Ares Credit Facility will require the Company to comply with certain affirmative non-financial covenants relating to periodic reporting and maintaining compliance with standard rules and regulations customary in the markets where the Company competes, as well as negative financial covenants limiting levels of indebtedness and restricting certain payments, as well as minimum revenue covenants for each twelve-month period ending December 31, 2018, March 31, 2019 and June 30, 2019, minimum consolidated adjusted EBITDA covenants for the twelve-month period ending September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020 and September 30, 2020 and minimum net leverage ratio covenants for the twelve-month period ending December 31, 2020 and ending each fiscal quarter thereafter until maturity . The 2023 Term Loan and 2023 Delayed Draw Term Loan will be subordinate to the 2022 Revolver. The proceeds from both the 2022 Revolver and 2023 Term Loan are anticipated to be funded in the fourth quarter upon execution of the final agreements with Ares, whereas the 2023 Delayed Draw Term Loan will be made available when the Company initiates capital improvements to substantially increase manufacturing capacity in its Buena, New Jersey injectable manufacturing facility, which is currently scheduled to begin in fiscal year 2019. The Company intends to use the proceeds from 2023 Term Loan to extinguish its existing $25.0 million 2021 Term Loan, as well as extinguish its remaining outstanding $68.7 million of December 2019 Notes. The 2022 Revolver will bear interest at a rate of LIBOR plus 3.75%, whereas the 2023 Term Loan and 2023 Delayed Draw Term Loan will bear interest at a rate of LIBOR plus 8.75% with a 24-month paid-in-kind interest option available to the Company should it choose to defer cash interest payments in order to provide further liquidity to continue launching new products. · Out of Period Adjustments For the three and nine months ended September 30, 2018, the Company recorded the following adjustments (in thousands) related to prior periods. The net impact of the adjustments on all prior annual or interim periods financial statements were not significant. There were no adjustments related to prior periods recorded for the three and nine months ended September 30, 2017. Three months ended Nine months ended September 30, 2018 September 30, 2018 Wholesale fees (Revenue) $ — $ 1,218 Chargebacks (Revenue) (455) (455) Medicaid (Revenue) — 297 Pricing and shipment adjustment (Revenue) — (502) Sales return reserve (Revenue) — (577) Inventory adjustments (Cost of revenues) — 95 Capitalization of property, plant and equipment (Cost of revenues) — 263 Bad debt expense (Selling, general and administrative expenses) — (578) $ (455) $ (239)

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Teligent, Inc. and its wholly-owned and majority-owned subsidiaries. All inter-company accounts and transactions have been eliminated. The Company consolidated the following entities: Igen, Inc., Teligent Pharma. Inc., Teligent Luxembourg S.à.r.l., Teligent OÜ, Teligent Canada Inc., and Teligent Jersey Limited., in addition to the following inactive entities: Microburst Energy, Inc., Blood Cells, Inc. and Flavorsome, Ltd. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the historical valuation of the derivative liability, sales returns and allowances, allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related valuation allowances, stock based compensation, the assessment for the impairment of long-lived assets (including intangibles, goodwill and property, plant and equipment), property, plant and equipment and legal accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates. Cash Equivalents The Company considers all highly liquid instruments purchased with the original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Cash and cash equivalents include cash on hand and bank demand deposits used in the Company’s cash management program. The Company has restricted cash, consisting of escrow accounts and letter of credits, which is included within other assets on the Condensed Consolidated Balance Sheet. The Company also presents restricted cash with cash and cash equivalents in the Condensed Consolidated Statement of Cash Flows. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheet to the total amounts in the Condensed Consolidated Statement of Cash Flows as follows (in thousands): September 30, 2018 December 31, 2017 September 30, 2017 December 31, 2016 Cash and cash equivalents $ 15,267 $ 26,692 $ 38,231 $ 66,006 Restricted cash in other assets 472 473 475 475 Cash, cash equivalents and restricted cash in the statement of cash flows $ 15,739 $ 27,165 $ 38,706 $ 66,481 Stock Based Compensation ASC 718-10 defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options, restricted stock units ("RSU's") and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions. Stock-based compensation expense is recognized over the requisite service period of the award, which usually coincides with the vesting period of the grant. Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, trade receivables, notes payable, accounts payable and other accrued liabilities at September 30, 2018 approximate their fair value for all periods presented. As of September 30, 2018, the net carrying value of the 2019 Notes and 2023 Notes (collectively the "Notes" and discussed in Note 7) was approximately $117.8 million compared to their face value of $143.75 million. This variance is due to the conversion feature in the Notes rather than to changes in market interest rates. The Notes carry a fixed interest rate and therefore are not subject to interest rate risk. As of September 30, 2018, the carrying value of the 2021 Term Loan (discussed in Note 7) was approximately $24.2 million compared to the face value of $25.0 million. The variance is due to debt discount and debt financing costs. The 2021 Term Loan bears interest at a rate of LIBOR plus 9%, and is therefore subject to market risk. Loss Per Share Basic loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the conversion of the 2019 and 2023 Notes, the exercise of options, and the vesting of RSU's. For the three and nine months ended September 30, 2018, the potential dilutive common stock equivalents have been excluded from the computation of diluted loss per share, as their effect would have been anti-dilutive. (in thousands except shares and per share data) Three months ended September 30, Nine months ended September 30, 2018 2017 2018 2017 Basic loss per share computation: Net loss - basic and diluted $ (3,945) $ (8,982) $ (21,866) $ (9,070) Weighted average common shares - basic and diluted 53,625,768 53,391,948 53,532,277 53,297,889 Basic and diluted loss per share $ (0.07) $ (0.17) $ (0.41) $ (0.17) Revenue Recognition The Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The Company's revenue is recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. The Company derives its revenues from three types of transactions: sales of its own pharmaceutical products (Company product sales), sales of manufactured product for its customers (contract manufacturing sales), and research and product development services performed for third parties. Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each. Taxes collected from customers and remitted to government authorities and that are related to the sales of the Company’s products are excluded from revenues. See more detailed information in Note 4. Adoption of ASC Topic 606, "Revenue from Contracts with Customers” In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” The standard, including subsequently issued amendments, replaces most existing revenue recognition guidance in U.S. GAAP. The key focus of the new standard is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performed a comprehensive review of its existing revenue arrangements as of January 1, 2018 following the five-step model as discussed in Note 4. Based on the Company's analysis, there were no changes identified that impacted the amount or timing of revenues recognized under the new guidance as compared to the previous guidance. Additionally, the Company's analysis indicated that there were no changes to how costs to obtain and fulfill our customer contracts would be recognized under the new guidance as compared to the previous guidance. The impact of the adoption of this standard on the Company's Condensed Consolidated Balance Sheet, Condensed Consolidated Statement of Operations, and Condensed Consolidated Statement of Cash Flows was not material. The adoption of the new guidance impacted the way the Company analyzes, documents, and discloses revenue recognition under customer contracts beginning on January 1, 2018 and resulted in additional disclosures in the Company's financial statements. Property, Plant and Equipment Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows: Useful Lives Buildings and Improvements 10 - 40 years Machinery and Equipment 5 - 15 years Computer Hardware and Software 3 - 5 years Furniture Fixtures 5 years Leasehold improvements are amortized over the shorter of estimated useful life or the lease term. Repair and maintenance costs are charged to operations as incurred while major improvements are capitalized. Construction in progress ("CIP") costs are amortized based on the asset class when they are put into service. When assets are retired or disposed, the related cost and accumulated depreciation thereon are removed and any gains or losses are included in operating results. Concentration of Credit Risk Major customers of the Company are defined as those constituting greater than 10% of our total revenue. For the three months ended September 30, 2018, three of the Company’s customers accounted for 49% of the Company’s revenue, consisting of 25%, 12% and 12%, respectively. For the three months ended September 30, 2017, three of the Company’s customers accounted for 54% of the Company’s revenue, consisting of 33%, 11% and 10%, respectively. For the nine months ended September 30, 2018, three of the Company's customers accounted for 54% of the Company's revenue, consisting of 32%, 12% and 10%, respectively. For the nine months ended September 30, 2017, three of the Company's customers accounted for 52% of the Company's revenue, consisting of 28%, 12% and 12%, respectively. Accounts receivable related to the Company’s major customers comprised 56% of all accounts receivable as of September 30, 2018, and 74% of all accounts receivable as of September 30, 2017. The loss of one or more of these major customers could have a significant impact on our revenues and harm our business and results of operations . For the three months ended September 30, 2018, domestic net revenues were $13.3 million and foreign net revenues were $5.0 million. For the nine months ended September 30, 2018, domestic net revenues were $34.9 million and foreign net revenues were $14.2 million. As of September 30, 2018, domestic assets were $131.9 million and foreign assets were $61.0 million. For the three months ended September 30, 2017, domestic net revenues were $8.7 million and foreign net revenues were $2.6 million. For the nine months ended September 30, 2017, domestic net revenues were $36.5 million and foreign net revenues were $8.9 million. As of September 30, 2017, domestic assets were $121.2 million and foreign assets were $69.5 million. Foreign Currency Translation The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in Accumulated Other Comprehensive Loss ("AOCI") and reflected as a separate component of equity. For those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Foreign currency exchange gain (loss) line item under the Other income (expense), section of the Condensed Consolidated Statement of Operations. Debt Issuance Costs Expenses related to debt financing activities are capitalized and amortized on an effective interest method, over the term of the loan and are to be netted against the carrying value of the financial liability, as required by ASU 2015-3. This standard aligns the treatment of debt issuance costs and debt discounts in that both reduce the carrying value of the liability. Amortization of debt issuance costs are recorded as interest expense on the Condensed Consolidated Statement of Operations. Adoption of Other Recent Accounting Pronouncements In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): "Restricted Cash (a consensus of the FASB Emerging Issues Task Force)". The update addresses the diversity in the industry with respect to classification and presentation of changes in restricted cash on the statement of cash flows. These amendments require that a statement of cash flows explain the restricted cash change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The amendments in this update were effective for fiscal years beginning after December 15, 2017 for public business entities, including interim periods within those fiscal years. For the Company, the amendments were effective January 1, 2018. The Company's adoption of this ASU was a full retrospective adoption, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): “Clarifying the Definition of a Business”. The update clarifies the definition of a business, specifically for companies to better evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update were effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those annual periods. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. In January 2017, the FASB issued ASU 2017-03, Accounting Changes and Error Corrections (Topic 250) and Investments-Equity Method and Joint Ventures (Topic 323): “Amendments to SEC Paragraphs Pursuant to Staff Announcements at the September 22, 2016 and November 17, 2016 EITF Meetings”. The update shows amendments to two SEC Announcements made late in 2016 regarding four specific standards as follows: ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ASU 2016-02, Leases (Topic 842), ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), and ASU 2014-01, Investments - Equity Method and Joint Ventures (Topic 323). The amendments in this update require changes to the U.S. GAAP Financial Reporting Taxonomy and the changes will be incorporated into the proposed 2018 Taxonomy which are available for public comment and finalized as part of the annual release process. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. In February 2017, the FASB issued ASU 2017-05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): “Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets”. This update addresses guidance for partial sales of nonfinancial assets. It affects (i) an entity that enters into a contract to transfer to a customer a nonfinancial asset, group of nonfinancial assets, or ownership interest in a consolidated subsidiary that is not a business or nonprofit entity, (ii) an entity that historically had transactions within the scope of the real estate-specific derecognition guidance, and (iii) an entity that contributes nonfinancial assets that are not a business or a nonprofit activity to a joint venture or other noncontrolled investee. The amendments were effective at the same time as the amendments in ASU 2014-09. Therefore, for the Company, the amendments were effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Public entities may apply the guidance earlier but only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company does not currently expect to enter into any such nonfinancial asset or ownership interest in its consolidated subsidiaries agreements but will refer to the guidance in ASU 2017-05 should that occur. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): “Scope of Modification Accounting”. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments affect any entity that changes the terms or conditions of a share-based payment award. The amendments are effective for fiscal years beginning after December 15, 2017. For the Company, the amendments were effective January 1, 2018. The Company has not made any changes to the terms or conditions of share-based payment awards but will refer to the guidance in ASU 2017-09 should that occur. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): “Recognition and Measurement of Financial Assets and Financial Liabilities”. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. In July 2018, the FASB issued ASU 2018-11. The targeted improvements in the ASU provides: - an option to apply the transition provisions of the new standard at its adoption date instead of at the earliest comparative period presented in its financial statements, and - a practical expedient that permits lessors to not separate nonlease components from the associated lease component if certain conditions are met. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company is reviewing all lease agreements inclusive of supplier agreements. The Company is currently evaluating the impact of this ASU on its condensed consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): “Simplifying the Test for Goodwill Impairment”. The update simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. For the Company, the amendments are effective January 1, 2020. The Company is currently evaluating the impact of this ASU on its condensed consolidated financial statements. In February 2018, the FASB issued ASU 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,” which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. This guidance is effective for all entities for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. The amendments in ASU 2018-02 should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this guidance is not expected to have a material impact on the Company's condensed consolidated financial statements and related disclosures.

Revenues, Recognition and Allow

Revenues, Recognition and Allowances	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenues, Recognition and Allowances	Revenues, Recognition and Allowances Revenue Recognition As of January 1, 2018, the Company adopted the ASC 606 guidance for revenue recognition for contracts, using the modified retrospective method. The implementation of this guidance had no material impact on the measurement or recognition of revenue from customer contracts of prior periods. Upon adoption of this new guidance, the Company recognizes revenue using the following five steps: • Identification of the contract, or contracts, with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price, including the identification and estimation of variable consideration; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when we satisfy a performance obligation. The Company derives its revenues from three types of transactions: sales of its own pharmaceutical products (Company product sales), sales of manufactured product for its customers (contract manufacturing sales), and research and product development services performed for third parties. Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience as well as applicable information currently available. Company Product Sales Revenue from Company product sales is recognized upon transfer of control of a product to a customer at a point in time, generally as the Company's products are sold on an FOB destination basis and because inventory risk and risk of ownership passes to the customer upon delivery. Company product sales are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. Contract Manufacturing Sales The Company recognizes revenue for contract manufacturing sales over-time, as milestones are achieved. Shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. Contract manufacturing sales are recognized net of accruals for cash discounts and returns which are established at the time of sale, and are included in Revenue, net in the Company's Condensed Consolidated Statement of Operations. Research and Development Services and Other Income The Company establishes agreed upon product development agreements with its customers to perform product development services. Revenues are recognized in accordance with the agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Other types of revenue include royalty or licensing revenue, and would be recognized over time, or at a point in time, based upon the contractual term upon completion of the earnings process. Judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Revenues by Transaction Type The Company operates in one reportable segment and, therefore, the results of the Company's operations are reported on a consolidated basis, consistent with internal management reporting for the chief decision makers. Net Sales (in thousands) for the three and nine months ended September 30, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption): Three months ended September 30, Nine months ended September 30, 2018 2017 2018 2017 Company product sales $ 16,375 $ 9,436 $ 44,288 $ 37,556 Contract manufacturing sales 1,878 1,883 4,626 7,707 Research and development services and other income 41 21 $ 174 $ 172 Revenue, net $ 18,294 $ 11,340 $ 49,088 $ 45,435 Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations, and is presented below according to contract type (in thousands): Three months ended September 30, Nine months ended September 30, Company Product Sales 2018 2017 2018 2017 Topical $ 10,503 $ 5,913 $ 26,297 $ 22,066 Injectables 5,872 3,523 17,991 15,490 Total $ 16,375 $ 9,436 $ 44,288 $ 37,556 In the nine months ended September 30, 2018, Company did not incur, and therefore did not defer, any material incremental costs to obtain contracts. Returns and Allowances As is customary in the pharmaceutical industry, the Company’s product sales are subject to a variety of deductions including chargebacks, rebates, cash discounts, other allowances, and returns. Product sales are recorded net of accruals for returns and allowances, which are established at the time of sale. The Company analyzes the adequacy of its accruals for returns and allowances quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. These provisions are estimates based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The Company uses a variety of methods to assess the adequacy of its returns and allowances reserves to ensure that its financial statements are fairly stated. These include periodic reviews of customer inventory data, customer contract programs, subsequent actual payment experience, and product pricing trends to analyze and validate the return and allowances reserves. Accounts receivable are presented net of returns and allowances balances of $20.5 million and $31.8 million at September 30, 2018 and 2017, respectively. The allowance for doubtful accounts was $2.8 million and $2.2 million at September 30, 2018 and 2017, respectively. These balances are primarily related to one specific customer in the amount of $1.7 million. Chargebacks are one of the Company's most significant estimates for recognition of product sales. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by its wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from its largest wholesale customers. This customer inventory information is used to establish the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent a majority of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Rebates are used for various discounts and rebates provided to customers. This account has been used for various one-time discounts given to customers. The Company reviews the percentage of products sold through these programs by reviewing chargeback data and uses the appropriate percentages to calculate the rebate accrual. Rebates are invoiced monthly or quarterly and reviewed against the accruals. Other items that could be included in accrued rebates would be price protection fees, shelf stock adjustments (SSAs), or other various amounts that would serve as one time discounts on specific products. The Company's adjustments for the deductions to gross product sales are as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2018 2017 2018 2017 Gross product sales $ 40,111 $ 53,460 $ 124,801 $ 174,504 Deduction to gross product sales: Chargebacks and billbacks 10,739 30,954 49,103 105,059 Wholesaler fees for service 1,662 1,511 2,774 5,715 Sales discounts and other allowances 11,335 11,559 28,636 26,174 Total reduction to gross product sales $ 23,736 $ 44,024 $ 80,513 $ 136,948 Company product sales, net $ 16,375 $ 9,436 $ 44,288 $ 37,556 Financing and Payment The Company's payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant. Generally, the Company does not incur incremental costs to obtain contracts. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because the Company's customers generally pay the Company within 100 days. Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in selling, general and administrative expense in the Condensed Consolidated Statements of Operations. Costs related to shipping and handling are comprised of outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of sales in the Condensed Consolidated Statements of Operations.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventories	InventoriesInventories are valued at the lower of cost or net realizable value, using the first-in-first-out method and consist of the following (in thousands): September 30, 2018 December 31, 2017 Raw materials $ 11,093 $ 8,231 Work in progress 2,000 616 Finished goods 6,937 8,532 Inventories reserve (2,148) (1,304) Inventories, net $ 17,882 $ 16,075

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consists of the following (in thousands): September 30, 2018 December 31, 2017 Land $ 401 $ 257 Building and improvements 17,486 8,613 Machinery and equipment 10,172 9,142 Computer hardware and software 4,111 3,244 Furniture and fixtures 519 449 Construction in progress 65,510 55,017 98,199 76,722 Less accumulated depreciation and amortization (9,812) (8,367) Property, plant and equipment, net $ 88,387 $ 68,355 The Company recorded depreciation expense of $0.6 million and $0.4 million for the three months ended September 30, 2018 and September 30, 2017, respectively. The Company recorded depreciation expense of $1.7 million and $1.3 million for the nine months ended September 30, 2018 and September 30, 2017, respectively. During the three months ended September 30, 2018 and September 30, 2017, there was $1.5 million of interest and $1.1 million of interest, respectively, capitalized as construction in progress. For the nine months ended September 30, 2018 and September 30, 2017, there was $4.4 million of interest and $2.3 million of interest, respectively, capitalized as construction in progress. This increase in capitalized interest is related to outstanding costs for the Company's facility expansion project in Buena. During the three months ended September 30, 2018 and September 30, 2017, there was $0.4 million of payroll costs and $0.2 million of payroll costs, respectively, capitalized into construction in progress. For the nine months ended September 30, 2018 and September 30, 2017, there was $1.5 million of payroll costs and $0.6 million of payroll costs, respectively, capitalized into construction in progress.

Debt

Debt	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Debt	Debt Convertible Notes On December 16, 2014, the Company issued $125.0 million aggregate principal amount of Convertible 3.75% Senior Notes, due 2019 (the “2019 Notes”). On December 22, 2014, the Company announced the closing of the initial purchasers’ exercise in full of their option to purchase an additional $18.75 million aggregate principal amount of 2019 Notes. The 2019 Notes bear interest at a fixed rate of 3.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2015, and mature on December 15, 2019, unless earlier repurchased, redeemed or converted. The 2019 Notes are convertible into shares of the Company’s common stock, cash or a combination thereof. On May 20, 2015, the Company received shareholder approval for the increase in the number of shares of common stock authorized and available for issuance upon conversion of the 2019 Notes. On April 27, 2018, the Company entered into separate exchange agreements with certain holders of the 2019 Notes. The agreements gave the holders the right to exchange, in aggregate, $75.1 million of the 2019 Notes for $75.1 million of new Convertible 4.75% Senior Notes due 2023 (the “2023 Notes”). The new 2023 Notes bear a fixed interest rate of 4.75% per year, payable semi-annually with the principal payable in May 2023. At the option of the holders, the 2023 Notes are convertible into shares of the Company’s common stock, cash or a combination thereof. The initial conversion rate is $224.71 per share, subject to certain adjustments, related to either the Company's stock price volatility, or the Company's declaration of a stock dividend, stock distribution, share combination or share split expected dividends or other anti-dilutive activities. In addition, holders will be entitled to receive additional shares of common stock for a potential increase of the conversion rate up to $280.90 per share under a make-whole provision in some circumstances. The Company incurred loan issue costs of $1.6 million upon issuance of the 2023 Notes. In accordance with accounting for convertible debt within the cash conversion guidance of ASC 470-20, we allocated the principal amount of the 2023 Notes between its liability and equity components. The carrying amount of the liability component was determined by measuring the fair value of a similar debt instrument of similar credit quality and maturity that did not have the conversion feature. The carrying amount of the equity component, representing the embedded conversion option, was determined by deducting the fair value of the liability component from the principal amount of the 2023 Notes as a whole. The equity component was recorded to additional paid-in capital and is not remeasured as long as it continues to meet the conditions for equity classification. The excess of the principal amount of the 2023 Notes over the carrying amount of the liability component was recorded as a debt discount of $19.0 million, and is being amortized to interest expense using the effective interest method through the maturity date. We allocated the total amount of transaction costs incurred to the liability and equity components using the same proportions as the proceeds from the 2023 Notes. Transaction costs attributable to the liability component were recorded as a direct deduction from the liability component of the 2023 Notes, and are being amortized to interest expense using the effective interest method through the maturity date. Transaction costs attributable to the equity component were netted with the equity component of the 2023 Notes in additional paid-in capital. The effective interest rate of the 2023 Notes, inclusive of the debt discount and issuance costs, is 12.10%. The exchange of $75.1 million of the 2019 Notes for the 2023 Notes is considered an extinguishment under ASC 470-50. The 2019 Notes are accounted for under cash conversion guidance ASC 470-20, which requires the Company to allocate the fair value of the consideration transferred upon settlement to the extinguishment of the liability component and the reacquisition of the equity component upon derecognition. In accordance with the aforementioned guidance, the Company recorded $2.5 million of non-cash interest expense as an extinguishment loss related to the 2019 Notes in the Condensed Consolidated Statement of Operations. In addition the Company recorded a $7.6 million reduction of Additional Paid in Capital in connection with the extinguishment of $75.1 million of the 2019 Notes. Term Loan On June 1, 2018, the Company entered into a credit agreement for $25.0 million secured by all Company assets, due June 1, 2021 (“2021 Term Loan”). The 2021 Term Loan has limited financial and non-financial covenants inclusive of a minimum cash carry balance of $5.0 million. The 2019 Notes and 2023 Notes are subordinate to the 2021 Term Loan. The first $15.0 million of loan proceeds was received on June 1, 2018. The remaining loan proceeds of $10.0 million were subject to closing conditions as defined in the agreement and were received on July 16, 2018. The 2021 Term Loan incurred loan issue costs of $0.5 million and a discount of $0.4 million. The discount is due to lender fees paid on the initial drawdown of $15.0 million. The issue costs and discount are recognized as interest expense over the term of the 2021 Term Loan. The 2021 Term Loan bears interest at a rate of LIBOR plus 9%, with a stated floor of 2%. The effective interest, inclusive of the debt discounts and issue costs is 12.78% as of September 30, 2018. As disclosed in Note 2, due to the lack of compliance with the non-financial covenant prescribed by our Term Loan, we reclassified the net carrying value of $24.2 million as current debt in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. At September 30, 2018 and December 31, 2017, the net carrying value of the debt and the remaining unamortized debt discounts and debt issuance costs were as follows (in thousands): September 30, 2018 December 31, 2017 Face amount of the 2019 Notes (non-current due December 2019) $ 68,660 $ 143,750 Face amount of the 2021 Loan (current due June 2021) 25,000 — Face amount of the 2023 Notes (non-current due May 2023) 75,090 — $ 168,750 $ 143,750 Less unamortized discounts and debt issuance costs 26,800 22,773 Total Carrying Value, Net $ 141,950 $ 120,977 For the nine months ended September 30, 2018 and 2017, the Company recorded the following expenses in relation to the debt (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Interest expense of the 2019 Notes (1) $ 644 $ 1,348 $ 2,870 $ 4,043 Interest expense of the 2021 Loan 659 — 800 — Interest expense of the 2023 Notes (1) 889 — 1,523 — Debt partial extinguishment of 2019 Notes — — 2,467 — Debt discount amortization of the 2019 Notes (1) 1,192 2,193 5,102 6,376 Debt discount amortization of the 2021 Loan 22 — 36 — Debt discount amortization of the 2023 Notes (1) 717 — 1,215 — Debt financing amortization of the 2019 Notes (1) 130 239 576 695 Debt financing amortization of the 2021 Loan 30 — 47 — Debt financing amortization of the 2023 Notes (1) 62 — 104 — Interest expense $ 4,345 $ 3,780 $ 14,740 $ 11,114

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The Company acquired the assets of Canadian pharmaceutical company Alveda Pharmaceuticals, Inc., in November 2015. As a result of the acquisition, we recorded goodwill of $0.4 million. We assess the recoverability of the carrying value of goodwill in the fourth quarter of each year, and whenever events occur or circumstances change that would, more likely than not, reduce the fair value of our reporting unit below its carrying value. There have been no events or changes in circumstances that would have reduced the fair value of our reporting unit below its carrying value from December 31, 2017, through September 30, 2018. No impairment losses were recognized during the nine months ended September 30, 2018. Changes to the carrying value of goodwill during the nine months ended September 30, 2018 and the year ending December 31, 2017 were as follows (in thousands): Goodwill Goodwill balance at December 31, 2016 $ 446 Foreign currency translation 25 Goodwill balance at December 31, 2017 $ 471 Foreign currency translation (7) Goodwill balance at September 30, 2018 $ 464 Intangible Assets The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of September 30, 2018 and December 31, 2017 (in thousands). September 30, 2018 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 39,167 $ (7,533) $ 31,634 11.1 In process research and development ("IPR&D") 17,765 — 17,765 N/A Customer relationships 3,695 (1,049) 2,646 7.1 Total $ 60,627 $ (8,582) $ 52,045 December 31, 2017 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 40,380 $ (5,684) $ 34,696 12.8 In-process research and development ("IPR&D") 18,311 — 18,311 N/A Customer relationships 3,783 (773) 3,010 7.9 Total $ 62,474 $ (6,457) $ 56,017 Changes in intangibles during the nine months ended September 30, 2018 were as follows (in thousands): Trademarks and Technology IPR&D Customer Relationships Balance at January 1, 2018 $ 34,696 $ 18,311 $ 3,010 Amortization (2,022) — (280) Loss on impairment (7) (15) — Foreign currency translation (1,033) (531) (84) Balance at September 30, 2018 $ 31,634 $ 17,765 $ 2,646 Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of September 30, 2018 over the remainder of 2018 and each of the next five years is estimated to be as follows (in thousands): Amortization Expense * 2018 (remainder of the year) $ 765 2019 3,061 2020 3,061 2021 3,061 2022 3,061 2023 3,061 Thereafter 18,210 Total $ 34,280 *IPR&D amounts are assessed for impairment at least annually and will be amortized once products are approved, including the product's respective manufacturing process approvals, and are not included in the table. The useful lives of the Company’s intangibles are as follows: Intangibles Category Amortizable Life Trademarks and Technology 15 Customer Relationships 10

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Options The Company recognized $0.4 million and $0.5 million of compensation expense related to stock options during the three months ended September 30, 2018 and 2017, respectively, and $1.2 million and $1.7 million during the nine months ended September 30, 2018 and 2017, respectively. The 1999 Director Stock Option Plan, as amended (the “Director Plan”), provides for the grant of stock options to non-employee directors of the Company at an exercise price equal to the fair market value per share on the date of the grant. As of December 31, 2017, an aggregate of 1,975,000 shares had been approved and authorized for issuance pursuant to the Director Plan with no change as of September 30, 2018. A total of 2,634,798 options had been granted to non-employee directors through December 31, 2017, with no change as of September 30, 2018. A total of 807,782 of those had been forfeited through December 31, 2017 and returned to the option pool for future issuance, with no change as of September 30, 2018. The options granted under the Director Plan vest in full one year after their respective grant dates and have a maximum term of ten years. As of December 31, 2017 and September 30, 2018 there were 500,000 shares of common stock options outstanding. As of December 31, 2017, the 147,984 options available were transferred to a plan that has superseded the Director Plan, as discussed further in this section, with no additional options transferred as of September 30, 2018. The 1999 Stock Incentive Plan, as amended (“1999 Plan”), replaced all previously authorized employee stock option plans, and no additional options may be granted under those previous plans. Under the 1999 Plan, options or stock awards may be granted to all of the Company’s employees, officers, directors, consultants and advisors to purchase a maximum of 3,200,000 shares of common stock. However, pursuant to the terms of the 1999 Plan, no awards may be granted after March 16, 2009. A total of 2,892,500 options, having a maximum term of ten years, have been granted at 100% of the fair market value of the Company’s common stock at the date of grant. Options outstanding under the 1999 Plan were generally exercisable in cumulative increments over four years commencing one year from date of grant. As of September 30, 2018, there are no options outstanding under the 1999 Plan. On June 26, 2009, the Board of Directors adopted, and the Company’s stockholders subsequently approved by written consent, the IGI Laboratories, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan became effective on July 29, 2009. The 2009 Plan allows the Company to continue to grant options and restricted stock, as under the 1999 Plan, but also authorizes the Board of Directors to grant a broad range of other equity-based awards, including stock appreciation rights, restricted stock units (“RSUs”) and performance awards. The 2009 Plan has been created, pursuant to and consistent with the Company's current compensation philosophy, to assist the Company in attracting, retaining and rewarding designated employees, directors, consultants and other service providers of the Company and its subsidiaries and affiliates, in a manner that will be cost efficient to the Company from both an economic and financial accounting perspective. On April 12, 2010, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2009 Plan to increase the number of shares of Common Stock available for grant under such plan by adding 2,000,000 shares of Common Stock. The 2009 Plan, as amended on May 29, 2010, authorizes up to 5,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2009 Plan. The maximum number of shares that may be subject to awards made to any individual in any single calendar year under the 2009 Plan is 1,000,000 shares. As of September 30, 2018, there were 22,710 RSUs outstanding, 1,493,960 shares of stock outstanding, and options to purchase 2,575,606 shares of common stock outstanding. As of December 31, 2017, there were 99,626 RSUs outstanding, 1,422,020 shares of stock outstanding and options to purchase 3,038,634 shares of common stock outstanding. As of December 31, 2017, the 249,052 options available were transferred to a plan that has superseded the 2009 Plan, as discussed further in this section. As of September 30, 2018, an additional 232,004 options available were transferred to the plan that superseded the 2009 plan. On May 25, 2016, the Board of Directors approved the Company’s 2016 Equity Incentive Plan (the “2016 Plan”). On May 21, 2018, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2016 Plan to increase the number of shares of Common Stock available for grant under such plan by adding 2,000,000 shares of Common Stock. The 2016 Plan, as amended, provides for the issuance of awards of up to 4,000,000 shares of the Company’s common stock, plus any shares of common stock that are represented by awards granted under our Director Plan and 2009 Plan that are forfeited, expire or are canceled without delivery of shares of common stock or which result in the forfeiture of shares of common stock back to the Company on or after May 25, 2016, up to 2,500,000 shares. Generally, shares of common stock reserved for awards under the 2016 Plan that lapse or are canceled, will be added back to the share reserve available for future awards. However, shares of common stock tendered in payment for an award or shares of common stock withheld for taxes will not be available again for grant. The 2016 Plan provides that no participant may receive awards for more than 1,000,000 shares of common stock in any fiscal year. As the 2016 Plan supersedes both the Director Plan and the 2009 Plan, any available shares from both are now incorporated into the 2016 Plan. As of September 30, 2018, there were 161,214 RSUs outstanding, 74,667 shares of common stock outstanding and options to purchase 1,319,738 shares of common stock outstanding under the 2016 Plan. As of December 31, 2017, there were 89,003 RSUs outstanding, 20,000 shares of common stock outstanding and options to purchase 761,176 shares of common stock outstanding under the 2016 Plan. As of September 30, 2018 and December 31, 2017, there were a total of 3,073,421 shares of common stock and 1,526,857 shares of common stock available under the 2016 Plan, respectively. As of September 30, 2018 and December 31, 2017, there were options to purchase 4,395,344 and 4,299,810 shares of common stock outstanding, respectively, collectively in the Director Plan, 2009 Plan, and the 2016 Plan. In the interest of maintaining consistency with the Company's 2016 Equity Incentive Plan, on March 13, 2017, the Company entered into (i) an amendment to the option agreements governing each option grant currently outstanding under the Company's 2009 Equity Incentive Plan, and (ii) an amendment to the RSU, agreements governing each RSU grant currently outstanding under the 2009 Plan. The amendments provide for the automatic vesting upon a change of control of the Company of each option grant and RSU grant, as applicable, outstanding under the 2009 Plan. The amendments had a de minimis value to the holders as of September 30, 2018, and therefore no additional stock compensation expense was recognized related to the amendments. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. Nine Months Ended September 30, Assumptions 2018 2017 Expected dividends — — Risk-free rate 2.38 % 2.00 % Expected volatility 53.2% - 72.5% 58.0% - 69.7% Expected term (in years) 3.2 - 3.3 years 3.2 - 3.3 years Expected volatility was calculated using the historical volatility of the Company's stock over the expected life of the options. The expected life of the options was estimated based on the Company's historical data. The risk free interest rate is based on U.S. Treasury yields for securities with terms approximating the terms of the grants. Forfeitures are recognized in the period they occur. The assumptions used in the Black-Scholes options valuation model are highly subjective, and can materially affect the resulting valuation. A summary of option activity under the Director Plan, the 2009 Plan and the 2016 Plan as of September 30, 2018 and changes during the period are presented below: Number of Options Weighted Average Exercise Price Outstanding as of January 1, 2018 4,299,810 $ 5.09 Issued 735,785 3.35 Exercised (236,000) 1.04 Forfeited (404,251) 7.71 Expired — — Outstanding as of September 30, 2018 4,395,344 $ 4.78 Exercisable as of September 30, 2018 3,247,214 $ 4.74 The following tables summarize information regarding options outstanding and exercisable at September 30, 2018: Outstanding: Range of Exercise Prices Stock Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life $0.79 - $1.50 1,510,000 $ 1.06 3.38 $1.51 - $5.50 898,207 3.22 8.35 $5.51 - $10.67 1,987,137 8.31 7.21 Total 4,395,344 $ 4.78 6.12 Exercisable: Range of Exercise Prices Stock Options Exercisable Weighted Average Exercise Price $0.79 - $1.50 1,510,000 $ 1.06 $1.51 - $5.50 196,666 2.72 $5.51 - $10.67 1,540,548 8.60 Total 3,247,214 $ 4.74 As of September 30, 2018, the intrinsic value of the options outstanding was $5.0 million and the intrinsic value of the options exercisable was $4.6 million. As of September 30, 2018, there was $1.6 million of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the Plan. The costs will be recognized through August 2021. Restricted Stock and RSUs The Company periodically grants restricted stock and RSU awards to certain officers and other employees that typically vest one Number of RSUs Weighted Average Exercise Price Non-vested balance at January 1, 2018 188,629 $ 8.27 Changes during the period: Shares granted 122,949 3.36 Shares vested (101,607) 9.07 Shares forfeited (26,047) 5.76 Non-vested balance at September 30, 2018 183,924 $ 4.90

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s income tax expense (benefit) was $(0.1) million and $0.02 million for the three months ended September 30, 2018 and 2017, respectively. For the same two periods, the effective tax rates were 3.4% and 0.3%, respectively. The Company’s income tax expense (benefit) was $(0.1) million and $0.1 million for the nine months ended September 30, 2018 and 2017, respectively and the effective tax rates were 0.4% and 1.5%, respectively. The income tax benefit during the three and nine months ended September 30, 2018 includes $0.1 million of foreign benefits recognized during the period. The Company excludes from the calculation of the effective tax rate any entities that are projected to operate at a loss, have no tax benefit that can reasonably be expected, and those entities which operate in a zero tax rate jurisdiction. Due to continuing operating losses in the United States, the tax provision is based on minimum U.S. state income taxes and the operations of certain foreign affiliates that are subject to taxes in their respective countries The Company has assessed the impacts of the changes resulting from the United States Tax Cuts and Jobs Act (“TCJA”) and has recognized an income tax benefit and a corresponding receivable of $0.1 million related to the recoverability of Alternative Minimum Tax Credits during the 4 th quarter of 2017. Deferred tax assets, liabilities and valuation allowances were remeasured at the new rate of 21% during the 4 th quarter of 2017. There was no income impact resulting from the remeasurement since all U.S. net deferred tax assets are fully reserved by the Company. In addition, the TCJA imposed a one-time transition tax on cumulative earnings, as defined, on foreign affiliates through December 31, 2017. This also had no impact on the earnings of the Company, since the included foreign affiliates operated at a cumulative deficit through December 31, 2017. Beginning in 2018, the Company’s net interest expense became subject to limitations imposed by the TCJA. Based on operating expectations, the Company will be subject to an interest expense limitation. Such limitation will serve to reduce the otherwise expected net operating loss and create an additional attribute related to the disallowed net interest expense and therefore is not expected to have an effect on earnings. The passage of TCJA also included a new tax imposed on the current earnings of foreign subsidiaries called Global Intangible Low-Taxed Income (“GILTI”). Due to the complexity of the new GLITI tax rules, the Company continues to evaluate this provision of the TCJA and the application of ASC 740, Income Taxes . The Company is allowed to make an accounting policy choice of either (1) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the “period cost method”) or (2) factoring such amounts into the Company's measurement of its deferred taxes (the “deferred method”). The Company's selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing its global income to determine whether it expects to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Whether the Company expects to have future U.S. inclusions in taxable income related to GILTI depends on not only the Company's current structure and estimated future results of global operations, but also its intent and ability to modify its structure. The Company's currently in the process of analyzing its structure, however for 2018 the Company’s foreign entities as a whole are expected to generate an operating loss. Therefore, the Company has not made any adjustments related to potential GILTI tax in its financial statements and has not made a policy decision regarding whether to record deferred tax on GILTI. While the Company has completed its provisional analysis of the income tax effects of the TCJA, the related tax effects may need to be adjusted, possibly materially, due to further refinement of our calculations, changes in interpretations and assumptions that we have made, additional guidance that may be issued by regulatory bodies, and actions and related accounting policy decisions we may take as a result of the new legislation. We will complete our analysis over the one-year measurement period from the enactment of the law as provided for by "Income Tax Accounting Implications of the Tax Cuts and Jobs Act" (SAB 118), and any adjustments during this measurement period will be included in net earnings from continuing operations as an adjustment to income tax expense in the reporting period(s) when such adjustments are determined. The Company evaluates the recoverability of its net deferred tax assets based on its history of operating results, its expectations for the future and expiration dates. The Company has concluded that it is more likely than not it will be unable to realize the net deferred tax assets in the immediate future and has established a valuation allowance for all U.S. and foreign net deferred tax assets. At December 31, 2017, the Company’s U.S. federal net operating loss carryforwards totaled $41.7 million. The Company’s ability to use net operating loss carry forwards is subject to limitation in future periods under certain provisions of Section 382 of the Internal Revenue Code of 1986, as amended, which limit the utilization of net operating losses upon a more than 50% change in ownership of the Company’s stock that is held by 5% or greater stockholders. The Company examined the application of Section 382 with respect to an ownership change that took place during 2010, as well as the limitation on the application of net operating loss carry forwards. The Company believes that operating losses subsequent to the change date in 2010 (aggregating $23.1 million) are not subject to Section 382 limitations. The Company has estimated that the annual limitation starting in 2010 aggregates from $1.0 million to $2.3 million per year including the effect of amortization of built in gains. The Company’s loss carryforwards may be further limited in the future if additional ownership changes occur. The Company is subject to the provisions of ASC 740-10-25, “ Income Taxes” (ASC 740) which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. For federal purposes, post 1998 tax years remain open to examination as a result of net operating loss carryforwards. The Company is currently open to audit by the appropriate state income taxing authorities for tax years 2013 to 2017. The Company has not recorded any liability for uncertain tax positions. Canadian taxing authorities have examined the returns of the Canadian affiliate for the years 2015 and 2016. The Company expects to receive the agency’s report and has preliminarily been informed that there will be no adjustments.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Other Income and Expenses [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses represent various obligations of the Company including certain operating expenses and taxes payable. As of September 30, 2018 and December 31, 2017, the largest components of accrued expenses were (in thousands): September 30, 2018 December 31, 2017 Interest expense $ 2,335 $ 240 Payroll 1,595 1,580 Professional fees 1,221 546 Inventory and Supplies 1,191 58 Capital expenditures 1,042 1,947 Rebates 343 83 Royalties 613 856 Clinical studies 593 596 Medicaid and Medicare 365 1,487 Income Tax 30 58 Other 1,109 650 $ 10,437 $ 8,101

Legal and U.S. Regulatory Proce

Legal and U.S. Regulatory Proceedings	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Legal and U.S. Regulatory Proceedings	Legal and U.S. Regulatory Proceedings The Company is involved from time to time in claims which arise in the ordinary course of business. In management's opinion, the Company has made adequate provision for potential liabilities, if any, arising from any such matters. However, litigation is inherently unpredictable, and the costs and other effects of pending or future litigation, governmental investigations, legal and administrative cases and proceedings (whether civil or criminal), settlements, judgments and investigations, claims and changes in any such matters, and developments or assertions by or against the Company relating to intellectual property rights and intellectual property licenses, could have a material adverse effect on its business, financial condition and operating results. To date, twelve putative class action antitrust lawsuits have been filed against the Company along with co-defendants, including Taro Pharmaceuticals U.S.A., Inc. and Perrigo New York Inc. One “opt-out” action has additionally been filed against the Company along with thirty-four generic manufacturer co-defendants regarding the pricing of econazole nitrate cream along with twenty-nine additional drug products not manufactured or sold by the Company. All actions have been consolidated by the Judicial Panel on Multidistrict Litigation to the Eastern District of Pennsylvania for pre-trial proceedings as part of the In re Generic Pharmaceuticals Pricing Antitrust Litigation matter, and the class actions have been consolidated into three actions: the direct purchaser, end payer and indirect reseller actions. The class plaintiffs seek to represent nationwide or state classes consisting of persons who directly purchased, indirectly purchased, paid and/or reimbursed patients for the purchase of generic econazole from July 1, 2014 until the time the defendants’ allegedly unlawful conduct ceased or will cease. On October 16, 2018 the court dismissed the class plaintiffs’ claims against the Company with leave to replead. The opt-out plaintiffs allege a conspiracy by thirty-five generic manufacturers to fix prices for thirty drug products, including econazole nitrate cream, in violation of federal antitrust laws. The opt-out plaintiffs seek treble damages for alleged price overcharges for the thirty drug products identified in the complaint during the alleged period of conspiracy, and also seek injunctive relief against the defendants. A motion to dismiss the opt-out plaintiffs’ complaint has not yet been filed. Due to the early stage of these cases, we are unable to form a judgment at this time as to whether an unfavorable outcome is either probable or remote or to provide an estimate of the amount or range of potential loss. We believe these cases are without merit, and we intend to vigorously defend against these claims. On October 20, 2017, a Demand for Arbitration was filed with the American Arbitration Association by Stayma Consulting Services, Inc. (“Stayma”) against the Company regarding the Company’s development and manufacture for Stayma of two generic drug products, one a lotion and one a cream, containing 0.05% of the active pharmaceutical ingredient flurandrenolide. The Company developed the two products and Stayma purchased commercial quantities of each; however, Stayma alleges that the Company breached agreements between the parties by developing an additional and different generic drug product, an ointment, containing flurandrenolide, and failing to meet certain contractual requirements. Stayma seeks monetary damages. Because discovery in this matter is ongoing, the Company is unable to form a judgment at this time as to whether an unfavorable outcome is either probable or remote or to provide an estimate of the amount or range of potential loss. The Company believes this case is without merit, and the Company intends to vigorously defend against these claims. The Company filed a counter-claim against Stayma for its failure to pay several past due invoices of approximately $1.7 million relating to the development and commercial supply of the two subject products. These invoices have been fully reserved.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the historical valuation of the derivative liability, sales returns and allowances, allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related valuation allowances, stock based compensation, the assessment for the impairment of long-lived assets (including intangibles, goodwill and property, plant and equipment), property, plant and equipment and legal accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid instruments purchased with the original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Cash and cash equivalents include cash on hand and bank demand deposits used in the Company’s cash management program.
Stock Based Compensation	Stock Based Compensation ASC 718-10 defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options, restricted stock units ("RSU's") and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions. Stock-based compensation expense is recognized over the requisite service period of the award, which usually coincides with the vesting period of the grant.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Earnings (Loss) Per Share	Loss Per Share
Revenue Recognition	Revenue Recognition The Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The Company's revenue is recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. The Company derives its revenues from three types of transactions: sales of its own pharmaceutical products (Company product sales), sales of manufactured product for its customers (contract manufacturing sales), and research and product development services performed for third parties. Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each. Taxes collected from customers and remitted to government authorities and that are related to the sales of the Company’s products are excluded from revenues. See more detailed information in Note 4. Adoption of ASC Topic 606, "Revenue from Contracts with Customers” In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” The standard, including subsequently issued amendments, replaces most existing revenue recognition guidance in U.S. GAAP. The key focus of the new standard is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performed a comprehensive review of its existing revenue arrangements as of January 1, 2018 following the five-step model as discussed in Note 4. Based on the Company's analysis, there were no changes identified that impacted the amount or timing of revenues recognized under the new guidance as compared to the previous guidance. Additionally, the Company's analysis indicated that there were no changes to how costs to obtain and fulfill our customer contracts would be recognized under the new guidance as compared to the previous guidance. The impact of the adoption of this standard on the Company's Condensed Consolidated Balance Sheet, Condensed Consolidated Statement of Operations, and Condensed Consolidated Statement of Cash Flows was not material. The adoption of the new guidance
Property, Plant and Equipment	Property, Plant and Equipment Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows: Useful Lives Buildings and Improvements 10 - 40 years Machinery and Equipment 5 - 15 years Computer Hardware and Software 3 - 5 years Furniture Fixtures 5 years Leasehold improvements are amortized over the shorter of estimated useful life or the lease term. Repair and maintenance costs are charged to operations as incurred while major improvements are capitalized. Construction in progress ("CIP") costs are amortized based on the asset class when they are put into service. When assets are retired or disposed, the related cost and accumulated depreciation thereon are removed and any gains or losses are included in operating results.
Concentration of Credit Risk	Concentration of Credit Risk
Foreign Currency Translation	Foreign Currency Translation The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in Accumulated Other Comprehensive Loss ("AOCI") and reflected as a separate component of equity. For those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Foreign currency exchange gain (loss) line item under the Other income (expense), section of the Condensed Consolidated Statement of Operations.
Debt Issuance Costs	Debt Issuance Costs Expenses related to debt financing activities are capitalized and amortized on an effective interest method, over the term of the loan and are to be netted against the carrying value of the financial liability, as required by ASU 2015-3. This standard aligns the treatment of debt issuance costs and debt discounts in that both reduce the carrying value of the liability. Amortization of debt issuance costs are recorded as interest expense on the Condensed Consolidated Statement of Operations.
Adoption of Recent Accounting Pronouncements and Recently Issued Accounting Pronouncements	Adoption of Other Recent Accounting Pronouncements In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): "Restricted Cash (a consensus of the FASB Emerging Issues Task Force)". The update addresses the diversity in the industry with respect to classification and presentation of changes in restricted cash on the statement of cash flows. These amendments require that a statement of cash flows explain the restricted cash change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The amendments in this update were effective for fiscal years beginning after December 15, 2017 for public business entities, including interim periods within those fiscal years. For the Company, the amendments were effective January 1, 2018. The Company's adoption of this ASU was a full retrospective adoption, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): “Clarifying the Definition of a Business”. The update clarifies the definition of a business, specifically for companies to better evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update were effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those annual periods. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. In January 2017, the FASB issued ASU 2017-03, Accounting Changes and Error Corrections (Topic 250) and Investments-Equity Method and Joint Ventures (Topic 323): “Amendments to SEC Paragraphs Pursuant to Staff Announcements at the September 22, 2016 and November 17, 2016 EITF Meetings”. The update shows amendments to two SEC Announcements made late in 2016 regarding four specific standards as follows: ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ASU 2016-02, Leases (Topic 842), ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), and ASU 2014-01, Investments - Equity Method and Joint Ventures (Topic 323). The amendments in this update require changes to the U.S. GAAP Financial Reporting Taxonomy and the changes will be incorporated into the proposed 2018 Taxonomy which are available for public comment and finalized as part of the annual release process. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. In February 2017, the FASB issued ASU 2017-05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): “Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets”. This update addresses guidance for partial sales of nonfinancial assets. It affects (i) an entity that enters into a contract to transfer to a customer a nonfinancial asset, group of nonfinancial assets, or ownership interest in a consolidated subsidiary that is not a business or nonprofit entity, (ii) an entity that historically had transactions within the scope of the real estate-specific derecognition guidance, and (iii) an entity that contributes nonfinancial assets that are not a business or a nonprofit activity to a joint venture or other noncontrolled investee. The amendments were effective at the same time as the amendments in ASU 2014-09. Therefore, for the Company, the amendments were effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Public entities may apply the guidance earlier but only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company does not currently expect to enter into any such nonfinancial asset or ownership interest in its consolidated subsidiaries agreements but will refer to the guidance in ASU 2017-05 should that occur. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): “Scope of Modification Accounting”. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments affect any entity that changes the terms or conditions of a share-based payment award. The amendments are effective for fiscal years beginning after December 15, 2017. For the Company, the amendments were effective January 1, 2018. The Company has not made any changes to the terms or conditions of share-based payment awards but will refer to the guidance in ASU 2017-09 should that occur. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its condensed consolidated financial statements. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): “Recognition and Measurement of Financial Assets and Financial Liabilities”. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. In July 2018, the FASB issued ASU 2018-11. The targeted improvements in the ASU provides: - an option to apply the transition provisions of the new standard at its adoption date instead of at the earliest comparative period presented in its financial statements, and - a practical expedient that permits lessors to not separate nonlease components from the associated lease component if certain conditions are met. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company is reviewing all lease agreements inclusive of supplier agreements. The Company is currently evaluating the impact of this ASU on its condensed consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): “Simplifying the Test for Goodwill Impairment”. The update simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. For the Company, the amendments are effective January 1, 2020. The Company is currently evaluating the impact of this ASU on its condensed consolidated financial statements. In February 2018, the FASB issued ASU 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,” which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. This guidance is effective for all entities for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. The amendments in ASU 2018-02 should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this guidance is not expected to have a material impact on the Company's condensed consolidated financial statements and related disclosures.

Correction to Previously Issu_2

Correction to Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Changes and Error Corrections [Abstract]
Schedule of Adjustments	The following tables summarize the effects of the Revision on the Company's unaudited interim condensed consolidated financial statements as of and for the three and nine-months ended September 30, 2017 (in thousands): Condensed Consolidated Statements of Operations Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 As Previously As Previously Reported Adjustment As Revised Reported Adjustment As Revised Revenue, net 12,851 1,511 (1) 11,340 51,150 5,715 (1) 45,435 Cost of revenues 10,313 1,511 (1) 8,802 29,641 5,715 (1) 23,926 Total costs and expenses 20,890 1,511 (1) 19,379 58,004 5,715 (1) 52,289 Condensed Consolidated Balance Sheet Condensed Consolidated Balance Sheet September 30, 2017 December 31, 2017 As Previously As Previously Reported Adjustment As Revised Reported Adjustment As Revised Accounts receivable, net 25,026 3,800 (1),(2) 21,226 18,143 5,401 (1),(2) 12,742 Total current assets 79,846 3,800 (1),(2) 76,046 64,532 5,401 (1),(2) 59,131 Total assets 194,466 3,800 (1),(2) 190,666 189,986 5,401 (1),(2) 184,585 Accrued expenses 16,372 3,800 (1),(2) 12,572 13,502 5,401 (1),(2) 8,101 Total current liabilities 25,237 3,800 (1),(2) 21,437 24,097 5,401 (1),(2) 18,696 Total liabilities 143,939 3,800 (1),(2) 140,139 145,233 5,401 (1),(2) 139,832 Total liabilities and stockholders' equity 194,466 3,800 (1),(2) 190,666 189,986 5,401 (1),(2) 184,585 Condensed Consolidated Statement of Cash Flows Nine Months Ended September 30, 2017 As Previously Reported Adjustment As Revised Cash flows from operating activities Accounts receivable (4,960) (2,469) (1),(2) (2,491) Accounts payable and accrued expenses 4,006 2,469 (1),(2) 1,537

Nature of the Business and Li_2

Nature of the Business and Liquidity (Tables)	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Out of Period Adjustments	For the three and nine months ended September 30, 2018, the Company recorded the following adjustments (in thousands) related to prior periods. The net impact of the adjustments on all prior annual or interim periods financial statements were not significant. There were no adjustments related to prior periods recorded for the three and nine months ended September 30, 2017. Three months ended Nine months ended September 30, 2018 September 30, 2018 Wholesale fees (Revenue) $ — $ 1,218 Chargebacks (Revenue) (455) (455) Medicaid (Revenue) — 297 Pricing and shipment adjustment (Revenue) — (502) Sales return reserve (Revenue) — (577) Inventory adjustments (Cost of revenues) — 95 Capitalization of property, plant and equipment (Cost of revenues) — 263 Bad debt expense (Selling, general and administrative expenses) — (578) $ (455) $ (239)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Restrictions on Cash and Cash Equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheet to the total amounts in the Condensed Consolidated Statement of Cash Flows as follows (in thousands): September 30, 2018 December 31, 2017 September 30, 2017 December 31, 2016 Cash and cash equivalents $ 15,267 $ 26,692 $ 38,231 $ 66,006 Restricted cash in other assets 472 473 475 475 Cash, cash equivalents and restricted cash in the statement of cash flows $ 15,739 $ 27,165 $ 38,706 $ 66,481
Schedule of Earnings Per Share, Basic and Diluted	For the three and nine months ended September 30, 2018, the potential dilutive common stock equivalents have been excluded from the computation of diluted loss per share, as their effect would have been anti-dilutive. (in thousands except shares and per share data) Three months ended September 30, Nine months ended September 30, 2018 2017 2018 2017 Basic loss per share computation: Net loss - basic and diluted $ (3,945) $ (8,982) $ (21,866) $ (9,070) Weighted average common shares - basic and diluted 53,625,768 53,391,948 53,532,277 53,297,889 Basic and diluted loss per share $ (0.07) $ (0.17) $ (0.41) $ (0.17)
Schedule Of Property, Plant and Equipment Useful Lives	Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows: Useful Lives Buildings and Improvements 10 - 40 years Machinery and Equipment 5 - 15 years Computer Hardware and Software 3 - 5 years Furniture Fixtures 5 years

Revenues, Recognition and All_2

Revenues, Recognition and Allowances (Tables)	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenues	Net Sales (in thousands) for the three and nine months ended September 30, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption): Three months ended September 30, Nine months ended September 30, 2018 2017 2018 2017 Company product sales $ 16,375 $ 9,436 $ 44,288 $ 37,556 Contract manufacturing sales 1,878 1,883 4,626 7,707 Research and development services and other income 41 21 $ 174 $ 172 Revenue, net $ 18,294 $ 11,340 $ 49,088 $ 45,435 Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations, and is presented below according to contract type (in thousands): Three months ended September 30, Nine months ended September 30, Company Product Sales 2018 2017 2018 2017 Topical $ 10,503 $ 5,913 $ 26,297 $ 22,066 Injectables 5,872 3,523 17,991 15,490 Total $ 16,375 $ 9,436 $ 44,288 $ 37,556
Schedule of Accounts, Notes, Loans and Financing Receivable	The Company's adjustments for the deductions to gross product sales are as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2018 2017 2018 2017 Gross product sales $ 40,111 $ 53,460 $ 124,801 $ 174,504 Deduction to gross product sales: Chargebacks and billbacks 10,739 30,954 49,103 105,059 Wholesaler fees for service 1,662 1,511 2,774 5,715 Sales discounts and other allowances 11,335 11,559 28,636 26,174 Total reduction to gross product sales $ 23,736 $ 44,024 $ 80,513 $ 136,948 Company product sales, net $ 16,375 $ 9,436 $ 44,288 $ 37,556

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories are valued at the lower of cost or net realizable value, using the first-in-first-out method and consist of the following (in thousands): September 30, 2018 December 31, 2017 Raw materials $ 11,093 $ 8,231 Work in progress 2,000 616 Finished goods 6,937 8,532 Inventories reserve (2,148) (1,304) Inventories, net $ 17,882 $ 16,075

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment consists of the following (in thousands): September 30, 2018 December 31, 2017 Land $ 401 $ 257 Building and improvements 17,486 8,613 Machinery and equipment 10,172 9,142 Computer hardware and software 4,111 3,244 Furniture and fixtures 519 449 Construction in progress 65,510 55,017 98,199 76,722 Less accumulated depreciation and amortization (9,812) (8,367) Property, plant and equipment, net $ 88,387 $ 68,355

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Convertible Debt	At September 30, 2018 and December 31, 2017, the net carrying value of the debt and the remaining unamortized debt discounts and debt issuance costs were as follows (in thousands): September 30, 2018 December 31, 2017 Face amount of the 2019 Notes (non-current due December 2019) $ 68,660 $ 143,750 Face amount of the 2021 Loan (current due June 2021) 25,000 — Face amount of the 2023 Notes (non-current due May 2023) 75,090 — $ 168,750 $ 143,750 Less unamortized discounts and debt issuance costs 26,800 22,773 Total Carrying Value, Net $ 141,950 $ 120,977
Schedule of Debt Expense	For the nine months ended September 30, 2018 and 2017, the Company recorded the following expenses in relation to the debt (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Interest expense of the 2019 Notes (1) $ 644 $ 1,348 $ 2,870 $ 4,043 Interest expense of the 2021 Loan 659 — 800 — Interest expense of the 2023 Notes (1) 889 — 1,523 — Debt partial extinguishment of 2019 Notes — — 2,467 — Debt discount amortization of the 2019 Notes (1) 1,192 2,193 5,102 6,376 Debt discount amortization of the 2021 Loan 22 — 36 — Debt discount amortization of the 2023 Notes (1) 717 — 1,215 — Debt financing amortization of the 2019 Notes (1) 130 239 576 695 Debt financing amortization of the 2021 Loan 30 — 47 — Debt financing amortization of the 2023 Notes (1) 62 — 104 — Interest expense $ 4,345 $ 3,780 $ 14,740 $ 11,114

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes to the carrying value of goodwill during the nine months ended September 30, 2018 and the year ending December 31, 2017 were as follows (in thousands): Goodwill Goodwill balance at December 31, 2016 $ 446 Foreign currency translation 25 Goodwill balance at December 31, 2017 $ 471 Foreign currency translation (7) Goodwill balance at September 30, 2018 $ 464
Schedule of Finite and Indefinite Lived Intangible Assets	The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of September 30, 2018 and December 31, 2017 (in thousands). September 30, 2018 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 39,167 $ (7,533) $ 31,634 11.1 In process research and development ("IPR&D") 17,765 — 17,765 N/A Customer relationships 3,695 (1,049) 2,646 7.1 Total $ 60,627 $ (8,582) $ 52,045 December 31, 2017 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 40,380 $ (5,684) $ 34,696 12.8 In-process research and development ("IPR&D") 18,311 — 18,311 N/A Customer relationships 3,783 (773) 3,010 7.9 Total $ 62,474 $ (6,457) $ 56,017
Schedule of Changes in Intangible Assets Other Than Goodwill	Changes in intangibles during the nine months ended September 30, 2018 were as follows (in thousands): Trademarks and Technology IPR&D Customer Relationships Balance at January 1, 2018 $ 34,696 $ 18,311 $ 3,010 Amortization (2,022) — (280) Loss on impairment (7) (15) — Foreign currency translation (1,033) (531) (84) Balance at September 30, 2018 $ 31,634 $ 17,765 $ 2,646
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of September 30, 2018 over the remainder of 2018 and each of the next five years is estimated to be as follows (in thousands): Amortization Expense * 2018 (remainder of the year) $ 765 2019 3,061 2020 3,061 2021 3,061 2022 3,061 2023 3,061 Thereafter 18,210 Total $ 34,280 *IPR&D amounts are assessed for impairment at least annually and will be amortized once products are approved, including the product's respective manufacturing process approvals, and are not included in the table.
Schedule Of Intangible Assets, Useful Life	The useful lives of the Company’s intangibles are as follows: Intangibles Category Amortizable Life Trademarks and Technology 15 Customer Relationships 10

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Valuation Assumptions	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. Nine Months Ended September 30, Assumptions 2018 2017 Expected dividends — — Risk-free rate 2.38 % 2.00 % Expected volatility 53.2% - 72.5% 58.0% - 69.7% Expected term (in years) 3.2 - 3.3 years 3.2 - 3.3 years
Schedule of Stock Option Activity	A summary of option activity under the Director Plan, the 2009 Plan and the 2016 Plan as of September 30, 2018 and changes during the period are presented below: Number of Options Weighted Average Exercise Price Outstanding as of January 1, 2018 4,299,810 $ 5.09 Issued 735,785 3.35 Exercised (236,000) 1.04 Forfeited (404,251) 7.71 Expired — — Outstanding as of September 30, 2018 4,395,344 $ 4.78 Exercisable as of September 30, 2018 3,247,214 $ 4.74
Schedule of Stock Options Outstanding and Exercisable	The following tables summarize information regarding options outstanding and exercisable at September 30, 2018: Outstanding: Range of Exercise Prices Stock Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life $0.79 - $1.50 1,510,000 $ 1.06 3.38 $1.51 - $5.50 898,207 3.22 8.35 $5.51 - $10.67 1,987,137 8.31 7.21 Total 4,395,344 $ 4.78 6.12 Exercisable: Range of Exercise Prices Stock Options Exercisable Weighted Average Exercise Price $0.79 - $1.50 1,510,000 $ 1.06 $1.51 - $5.50 196,666 2.72 $5.51 - $10.67 1,540,548 8.60 Total 3,247,214 $ 4.74
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes the number of unvested RSUs and their weighted average exercise price for the nine months ended September 30, 2018. Number of RSUs Weighted Average Exercise Price Non-vested balance at January 1, 2018 188,629 $ 8.27 Changes during the period: Shares granted 122,949 3.36 Shares vested (101,607) 9.07 Shares forfeited (26,047) 5.76 Non-vested balance at September 30, 2018 183,924 $ 4.90

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Other Income and Expenses [Abstract]
Schedule of Accrued Expenses	As of September 30, 2018 and December 31, 2017, the largest components of accrued expenses were (in thousands): September 30, 2018 December 31, 2017 Interest expense $ 2,335 $ 240 Payroll 1,595 1,580 Professional fees 1,221 546 Inventory and Supplies 1,191 58 Capital expenditures 1,042 1,947 Rebates 343 83 Royalties 613 856 Clinical studies 593 596 Medicaid and Medicare 365 1,487 Income Tax 30 58 Other 1,109 650 $ 10,437 $ 8,101

Correction to Previously Issu_3

Correction to Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details Textual) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Reduction of revenue on wholesale fees	$ 1.5	$ 5.7
Reduction of accounts receivable on wholesale fees	6.1	6.1	$ 7
Increase (decrease) to accrued expenses, wholesale fees	(6.1)	(6.1)	7
Increase (decrease) to accrued expenses	2.3	2.3	1.6
Increase (decrease) to accounts receivable	$ 2.3	$ 2.3	$ 1.6

Correction to Previously Issu_4

Correction to Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue, net		$ 11,340		$ 45,435
Cost of revenues	$ 11,575	8,802	$ 32,365	23,926
Total costs and expenses	$ 19,507	19,379	$ 58,742	52,289
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue, net		12,851		51,150
Cost of revenues		10,313		29,641
Total costs and expenses		20,890		58,004
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue, net		1,511		5,715
Cost of revenues		1,511		5,715
Total costs and expenses		$ 1,511		$ 5,715

Correction to Previously Issu_5

Correction to Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 2) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net		$ 12,742	$ 21,226
Total current assets	$ 51,378	59,131	76,046
Total assets	192,882	184,585	190,666
Accrued expenses	10,437	8,101	12,572
Total current liabilities	39,081	18,696	21,437
Total liabilities	157,182	139,832	140,139
Total liabilities and stockholders' equity	$ 192,882	184,585	190,666
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net		18,143	25,026
Total current assets		64,532	79,846
Total assets		189,986	194,466
Accrued expenses		13,502	16,372
Total current liabilities		24,097	25,237
Total liabilities		145,233	143,939
Total liabilities and stockholders' equity		189,986	194,466
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net		5,401	3,800
Total current assets		5,401	3,800
Total assets		5,401	3,800
Accrued expenses		5,401	3,800
Total current liabilities		5,401	3,800
Total liabilities		5,401	3,800
Total liabilities and stockholders' equity		$ 5,401	$ 3,800

Correction to Previously Issu_6

Correction to Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 3) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable	$ (4,587)	$ (2,491)
Accounts payable and accrued expenses	$ (6,944)	1,537
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable		(4,960)
Accounts payable and accrued expenses		4,006
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable		(2,469)
Accounts payable and accrued expenses		$ 2,469

Nature of the Business and Li_3

Nature of the Business and Liquidity (Details Textual)	Nov. 13, 2018USD ($)	Sep. 30, 2018USD ($)segmentproduct	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)segment	Sep. 30, 2017USD ($)	Dec. 31, 2018USD ($)	Nov. 12, 2018USD ($)	Dec. 31, 2017USD ($)
Summary of Significant Accounting Policies Details [Line Items]
Segments | segment		1		1
Cash and cash equivalents		$ 15,267,000		$ 15,267,000				$ 26,692,000
Investments				18,300,000
Accumulated deficit		(81,960,000)		(81,960,000)				$ (60,094,000)
Net loss		(3,945,000)	$ (8,982,000)	(21,866,000)	$ (9,070,000)
Net cash used in operating activities				(15,314,000)	(2,660,000)
Reclassification of debt, net carrying value		24,200,000		24,200,000
Partial extinguishment of Convertible 3.75% Senior Notes		$ 0	$ 0	$ 2,467,000	$ 0
United States
Summary of Significant Accounting Policies Details [Line Items]
Generic products marketed | product		32
Branded generic products marketed | product		4
Minimum | Canada
Summary of Significant Accounting Policies Details [Line Items]
Generic and branded products marketed | product		30
Subsequent Event
Summary of Significant Accounting Policies Details [Line Items]
Shelf offering, suspended	$ 50,000,000
Ares Capital Management | Subsequent Event | Ares Credit Facility
Summary of Significant Accounting Policies Details [Line Items]
Letter of commitment letter outstanding							$ 120,000,000
Ares Capital Management | Subsequent Event | 2022 Revolver
Summary of Significant Accounting Policies Details [Line Items]
Letter of commitment letter outstanding							25,000,000
Ares Capital Management | Subsequent Event | 2023 Term Loan
Summary of Significant Accounting Policies Details [Line Items]
Letter of commitment letter outstanding							80,000,000
Ares Capital Management | Subsequent Event | 2023 Delayed Draw Term Loan
Summary of Significant Accounting Policies Details [Line Items]
Letter of commitment letter outstanding							$ 15,000,000
London Interbank Offered Rate (LIBOR) | 2022 Revolver
Summary of Significant Accounting Policies Details [Line Items]
Stated interest rate		3.75%		3.75%
London Interbank Offered Rate (LIBOR) | 2023 Term Loan
Summary of Significant Accounting Policies Details [Line Items]
Stated interest rate		8.75%		8.75%
London Interbank Offered Rate (LIBOR) | 2023 Delayed Draw Term Loan
Summary of Significant Accounting Policies Details [Line Items]
Stated interest rate		8.75%		8.75%
Forecast | 2021 Term Loan
Summary of Significant Accounting Policies Details [Line Items]
Repayments of debt						$ 25,000,000
Forecast | December 2019 Note
Summary of Significant Accounting Policies Details [Line Items]
Partial extinguishment of Convertible 3.75% Senior Notes						$ 68,700,000

Nature of the Business and Li_4

Nature of the Business and Liquidity (Details 1) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Summary of Significant Accounting Policies Details [Line Items]
Prior period reclassification adjustment	$ (455)	$ (239)
Wholesale fees (Revenue)
Summary of Significant Accounting Policies Details [Line Items]
Prior period reclassification adjustment	0	1,218
Chargebacks (Revenue)
Summary of Significant Accounting Policies Details [Line Items]
Prior period reclassification adjustment	(455)	(455)
Medicaid (Revenue)
Summary of Significant Accounting Policies Details [Line Items]
Prior period reclassification adjustment	0	297
Pricing and shipment adjustment (Revenue)
Summary of Significant Accounting Policies Details [Line Items]
Prior period reclassification adjustment	0	(502)
Sales return reserve (Revenue)
Summary of Significant Accounting Policies Details [Line Items]
Prior period reclassification adjustment	0	(577)
Inventory adjustments (Cost of revenues)
Summary of Significant Accounting Policies Details [Line Items]
Prior period reclassification adjustment	0	95
Capitalization of Property, Plant and Equipment (Cost of revenues)
Summary of Significant Accounting Policies Details [Line Items]
Prior period reclassification adjustment	0	263
Bad debt expense (Selling, general and administrative expenses)
Summary of Significant Accounting Policies Details [Line Items]
Prior period reclassification adjustment	$ 0	$ (578)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Cash and cash equivalents	$ 15,267	$ 26,692	$ 38,231	$ 66,006
Restricted cash in other assets	472	473	475	475
Cash, cash equivalents and restricted cash in the statement of cash flows	$ 15,739	$ 27,165	$ 38,706	$ 66,481

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Summary of Significant Accounting Policies Details [Line Items]
Product sales, net	$ 16,375	$ 9,436	$ 44,288	$ 37,556
Assets	192,882	190,666	192,882	190,666	$ 184,585
Domestic
Summary of Significant Accounting Policies Details [Line Items]
Product sales, net	13,300	8,700	34,900	36,500
Assets	131,900	121,200	131,900	121,200
Foreign
Summary of Significant Accounting Policies Details [Line Items]
Product sales, net	5,000	2,600	14,200	8,900
Assets	$ 61,000	$ 69,500	$ 61,000	$ 69,500
Sales Revenue | Customer concentration risk | Three Customers
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk	49.00%	54.00%	54.00%	52.00%
Sales Revenue | Customer concentration risk | Customer One
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk	25.00%	33.00%	32.00%	28.00%
Sales Revenue | Customer concentration risk | Customer Two
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk	12.00%	11.00%	12.00%	12.00%
Sales Revenue | Customer concentration risk | Customer Three
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk	12.00%	10.00%	10.00%	12.00%
Accounts Receivable
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk			56.00%	74.00%
Convertible Notes Payable
Summary of Significant Accounting Policies Details [Line Items]
Net carrying value of notes	$ 117,800		$ 117,800
Face value of notes	143,750		143,750
Term Loan 2021 | Convertible Notes Payable
Summary of Significant Accounting Policies Details [Line Items]
Net carrying value of notes	24,200		24,200
Face value of notes	$ 25,000		$ 25,000
London Interbank Offered Rate (LIBOR) | Term Loan 2021 | Convertible Notes Payable
Summary of Significant Accounting Policies Details [Line Items]
Basis spread on variable rate	9.00%		9.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 1) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Basic loss per share computation:
Net loss	$ (3,945)	$ (8,982)	$ (21,866)	$ (9,070)
Weighted average common shares - basic and diluted	53,625,768	53,391,948	53,532,277	53,297,889
Basic and diluted loss per share (in dollars per share)	$ (0.07)	$ (0.17)	$ (0.41)	$ (0.17)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 2)	9 Months Ended
	Sep. 30, 2018
Buildings and Improvements | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	10 years
Buildings and Improvements | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	40 years
Machinery and Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	5 years
Machinery and Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	15 years
Computer hardware and software | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	3 years
Computer hardware and software | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	5 years

Revenues, Recognition and All_3

Revenues, Recognition and Allowances (Details Textual) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018USD ($)transaction_typesegment	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)transaction_type	Sep. 30, 2018USD ($)transaction_typeproduct	Sep. 30, 2018USD ($)transaction_type	Sep. 30, 2018USD ($)transaction_typesegment	Sep. 30, 2018USD ($)transaction_type	Sep. 30, 2018USD ($)transaction_typedrug	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Disaggregation of Revenue [Line Items]
Types of transactions | transaction_type	3		3	3	3	3	3	3
Segments | segment	1					1
Accounts receivable		$ 21,226							$ 21,226	$ 12,742
Allowance for doubtful accounts	$ 2,787	2,200	$ 2,787	$ 2,787	$ 2,787	$ 2,787	$ 2,787	$ 2,787	2,200	2,185
Allowance for doubtful accounts related to one customer	1,700		$ 1,700	1,700	1,700	1,700	$ 1,700	1,700
Accounts receivable, terms of customer credit			100 days
Percentage of net sales for royalty							40.00%
Royalties	613	600	$ 613	$ 613	613	613	$ 613	$ 613	600	$ 856
Royalty expense	500	600			2,000				1,400
United States
Disaggregation of Revenue [Line Items]
Products which the company pays royalties				5				5
Products manufactured, marketed and distributed | drug								32
Net Of SRA Balance
Disaggregation of Revenue [Line Items]
Accounts receivable	$ 20,500	$ 31,800	$ 20,500	$ 20,500	$ 20,500	$ 20,500	$ 20,500	$ 20,500	$ 31,800

Revenues, Recognition and All_4

Revenues, Recognition and Allowances (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Company product sales, net	$ 16,375	$ 9,436	$ 44,288	$ 37,556
Research and development services and other income	41	21	174	172
Revenue, net	18,294	11,340	49,088	45,435
Company product sales
Disaggregation of Revenue [Line Items]
Company product sales, net	16,375	9,436	44,288	37,556
Topical
Disaggregation of Revenue [Line Items]
Company product sales, net	10,503	5,913	26,297	22,066
Injectables
Disaggregation of Revenue [Line Items]
Company product sales, net	5,872	3,523	17,991	15,490
Contract manufacturing sales
Disaggregation of Revenue [Line Items]
Company product sales, net	$ 1,878	$ 1,883	$ 4,626	$ 7,707

Revenues, Recognition and All_5

Revenues, Recognition and Allowances (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue from Contract with Customer [Abstract]
Gross Company product sales	$ 40,111	$ 53,460	$ 124,801	$ 174,504
Deduction to gross product sales:
Chargebacks and billbacks	10,739	30,954	49,103	105,059
Wholesaler fees for service	1,662	1,511	2,774	5,715
Sales discounts and other allowances	11,335	11,559	28,636	26,174
Total reduction to gross product sales	23,736	44,024	80,513	136,948
Company product sales, net	$ 16,375	$ 9,436	$ 44,288	$ 37,556

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 11,093	$ 8,231
Work in progress	2,000	616
Finished goods	6,937	8,532
Inventories reserve	(2,148)	(1,304)
Inventories, net	$ 17,882	$ 16,075

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property plant and equipment	$ 98,199	$ 76,722
Less accumulated depreciation and amortization	(9,812)	(8,367)
Property, plant and equipment, net	88,387	68,355
Land
Property, Plant and Equipment [Line Items]
Property plant and equipment	401	257
Building and improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment	17,486	8,613
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment	10,172	9,142
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment	4,111	3,244
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment	519	449
Construction in progress
Property, Plant and Equipment [Line Items]
Property plant and equipment	$ 65,510	$ 55,017

Property, Plant and Equipment_3

Property, Plant and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 600	$ 400	$ 1,703	$ 1,264
Interest costs capitalized			2,013	1,058
Construction in progress
Property, Plant and Equipment [Line Items]
Interest costs capitalized	1,500	1,100	4,400	2,300
Payroll costs	$ 400	$ 200	$ 1,500	$ 600

Debt (Details Textual)

Debt (Details Textual) - USD ($)	Jul. 16, 2018	Jun. 01, 2018	Apr. 27, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 22, 2014	Dec. 16, 2014
Debt Instrument [Line Items]
Partial extinguishment of equity component of Convertible 3.75% Senior Note						$ 7,600,000
Partial extinguishment of Convertible 3.75% Senior Notes				$ 0	$ 0	2,467,000	$ 0
Qualified Institutional Buyers
Debt Instrument [Line Items]
Face amount of the Notes									$ 18,750,000	$ 125,000,000
Convertible Note 2019
Debt Instrument [Line Items]
Face amount of the Notes				$ 68,660,000		$ 68,660,000		$ 143,750,000
Stated interest rate				3.75%		3.75%		3.75%
Non-cash interest expense				$ 2,500,000
Partial extinguishment of equity component of Convertible 3.75% Senior Note						$ (7,602,000)
Convertible Note 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate										3.75%
Debt, transfer			$ 75,100,000
Partial extinguishment of Convertible 3.75% Senior Notes			$ 75,100,000
Convertible Note 2023
Debt Instrument [Line Items]
Face amount of the Notes				$ 75,090,000		$ 75,090,000
Stated interest rate				4.75%		4.75%		4.75%
Convertible Note 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate			4.75%
Debt, transfer			$ 75,100,000
Initial conversion price (dollars per share)			$ 224.71
Settlement conversion price (dollars per share)			$ 280.90
Debt issuance costs			$ 1,600,000
Unamortized discount			$ 19,000,000
Interest rate, effective percentage			12.10%
Term Loan 2021
Debt Instrument [Line Items]
Face amount of the Notes		$ 25,000,000		$ 25,000,000		$ 25,000,000
Debt issuance costs		500,000
Unamortized discount		$ 400,000
Interest rate, effective percentage		12.78%
Covenant, minimum cash balance		$ 5,000,000
Proceeds from lines of credit	$ 10,000,000	$ 15,000,000
Floor interest rate		2.00%
Current debt				$ 24,200,000		$ 24,200,000
London Interbank Offered Rate (LIBOR) | Term Loan 2021
Debt Instrument [Line Items]
Basis spread on variable rate		9.00%

Debt (Details)

Debt (Details) - USD ($)	Sep. 30, 2018	Jun. 01, 2018	Dec. 31, 2017
Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes	$ 168,750,000		$ 143,750,000
Less unamortized discounts and debt issuance costs	26,800,000		22,773,000
Carrying amount of the Notes	141,950,000		120,977,000
Convertible Note 2019
Debt Instrument [Line Items]
Face amount of the Notes	68,660,000		143,750,000
Convertible Note 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes	68,660,000		143,750,000
Term Loan 2021
Debt Instrument [Line Items]
Face amount of the Notes	25,000,000	$ 25,000,000
Term Loan 2021 | Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes	25,000,000		0
Convertible Note 2023
Debt Instrument [Line Items]
Face amount of the Notes	75,090,000
Convertible Note 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes	$ 75,090,000		$ 0

Debt (Details 1)

Debt (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Debt Instrument [Line Items]
Debt partial extinguishment	$ 0	$ 0	$ 2,467	$ 0
Debt discount amortization			6,353	6,376
Debt financing amortization			727	695
Convertible Notes Payable
Debt Instrument [Line Items]
Interest expense	4,345	3,780	14,740	11,114
Convertible Note 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Interest expense	644	1,348	2,870	4,043
Debt partial extinguishment	0	0	2,467	0
Debt discount amortization	1,192	2,193	5,102	6,376
Debt financing amortization	130	239	576	695
Term Loan 2021 | Convertible Notes Payable
Debt Instrument [Line Items]
Interest expense	659	0	800	0
Debt discount amortization	22	0	36	0
Debt financing amortization	30	0	47	0
Convertible Note 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Interest expense	889	0	1,523	0
Debt discount amortization	717	0	1,215	0
Debt financing amortization	$ 62	$ 0	$ 104	$ 0

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Goodwill	$ 464,000	$ 471,000	$ 446,000
Impairment losses, goodwill	0
Alveda Pharmaceuticals
Goodwill [Line Items]
Goodwill	$ 400,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Goodwill [Roll Forward]
Goodwill beginning balance	$ 471	$ 446
Foreign currency translation	(7)	25
Goodwill ending balance	$ 464	$ 471

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Details 1) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, accumulated amortization	$ (8,582)	$ (6,457)
Total	52,045	56,017
Indefinite-lived Intangible Assets [Line Items]
Intangible assets gross carrying amount	60,627	62,474
Intangible assets net carrying amount	52,045	56,017
In process research and development (IPR&D)
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	17,765	18,311
Trademarks and Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	39,167	40,380
Finite-lived intangible assets, accumulated amortization	(7,533)	(5,684)
Total	$ 31,634	$ 34,696
Weighted average remaining amortization period	11 years 1 month 6 days	12 years 9 months 18 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	$ 3,695	$ 3,783
Finite-lived intangible assets, accumulated amortization	(1,049)	(773)
Total	$ 2,646	$ 3,010
Weighted average remaining amortization period	7 years 1 month 6 days	7 years 10 months 24 days

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Details 2) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	$ 56,017
Amortization	(2,302)	$ (2,143)
Finite-lived intangible assets ending balance	52,045
Indefinite-lived Intangible Assets [Roll Forward]
Loss on impairment	(22)	$ (113)
In process research and development (IPR&D)
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-lived intangible assets, beginning balance	18,311
Loss on impairment	(15)
Foreign currency translation	(531)
Indefinite-lived intangible assets, ending balance	17,765
Trademarks and Technology
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	34,696
Amortization	(2,022)
Impairment of Intangible Assets, Finite-lived	(7)
Foreign currency translation	(1,033)
Finite-lived intangible assets ending balance	31,634
Customer relationships
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	3,010
Amortization	(280)
Foreign currency translation	(84)
Finite-lived intangible assets ending balance	$ 2,646

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets (Details 3) $ in Thousands	Sep. 30, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2018 (remainder of the year)	$ 765
2,019	3,061
2,020	3,061
2,021	3,061
2,022	3,061
2,023	3,061
Thereafter	18,210
Total	$ 34,280

Goodwill and Intangible Asset_7

Goodwill and Intangible Assets (Details 4)	9 Months Ended
	Sep. 30, 2018
Trademarks and Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	15 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	10 years

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Textual) - USD ($) $ in Millions	May 25, 2016	May 29, 2010	Apr. 12, 2010	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Stock Based Compensation Details [Line Items]
Shares available for grant (in shares)								20,000,000
Unrecognized compensation costs				$ 1.6		$ 1.6
Employee Stock Option
Stock Based Compensation Details [Line Items]
Number of options issued (in shares)						735,785
Number of options forfeited (in shares)						404,251
Shares of common stock options outstanding (in shares)				4,395,344		4,395,344		4,299,810
Restricted Stock
Stock Based Compensation Details [Line Items]
Compensation expense				$ 0.1	$ 0.2	$ 0.4	$ 0.7
RSUs outstanding (in shares)								89,003,000
Unrecognized compensation costs				0.6		$ 0.6
Restricted Stock | Minimum
Stock Based Compensation Details [Line Items]
Vesting period						1 year
Restricted Stock | Maximum
Stock Based Compensation Details [Line Items]
Vesting period						3 years
Employee Stock Option
Stock Based Compensation Details [Line Items]
Compensation expense				$ 0.4	$ 0.5	$ 1.2	$ 1.7
Director Stock Option Plan - 1999
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)								1,975,000
Number of options issued (in shares)								2,634,798
Number of options forfeited (in shares)						807,782
Vesting period						1 year
Maximum term						10 years
Shares of common stock options outstanding (in shares)				500,000		500,000		500,000
Director Stock Option Plan - 1999 | Employee Stock Option
Stock Based Compensation Details [Line Items]
Shares available for grant (in shares)								147,984
1999 Stock Incentive Plan
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)				3,200,000		3,200,000
Number of options issued (in shares)						2,892,500
Vesting period						4 years
Maximum term						10 years
Shares of common stock options outstanding (in shares)				0		0
FMV common stock options granted (as a percent)						100.00%
Service period						1 year
Plan 2,009
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)		5,000,000
Number of options forfeited (in shares)	2,500,000
Shares of common stock options outstanding (in shares)				2,575,606		2,575,606		3,038,634
Shares available for grant (in shares)				1,493,960		1,493,960		1,422,020
Additional shares authorized (in shares)	2,000,000		2,000,000
Maximum number of shares to any individual (in shares)		1,000,000
Plan 2009 | Employee Stock Option
Stock Based Compensation Details [Line Items]
Shares available for grant (in shares)				232,004		232,004		249,052,000
Plan 2009 | Restricted Stock
Stock Based Compensation Details [Line Items]
RSUs outstanding (in shares)				22,710		22,710		99,626,000
Plan 2,016
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)	4,000,000
Shares of common stock options outstanding (in shares)				74,667		74,667		761,176,000
Shares available for grant (in shares)				3,073,421		3,073,421		1,526,857
Maximum number of shares to any individual (in shares)	1,000,000
Plan 2016 | Common Stock
Stock Based Compensation Details [Line Items]
Shares of common stock options outstanding (in shares)				1,319,738		1,319,738
Plan 2016 | Restricted Stock
Stock Based Compensation Details [Line Items]
RSUs outstanding (in shares)				161,214		161,214
Plan 2016, Plan 2009 And Director Plan | Employee Stock Option
Stock Based Compensation Details [Line Items]
Shares of common stock options outstanding (in shares)				4,395,344		4,395,344		4,299,810,000
Director Plan And The 2009 Plan
Stock Based Compensation Details [Line Items]
Intrinsic value of options outstanding				$ 5		$ 5
Intrinsic value of options exercisable				$ 4.6		$ 4.6

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Stock Based Compensation [Line Items]
Expected dividends	0.00%	0.00%
Risk-free rate	2.38%	2.00%
Minimum
Stock Based Compensation [Line Items]
Expected volatility	53.20%	58.00%
Expected term (in years)	3 years 2 months 12 days	3 years 2 months 12 days
Maximum
Stock Based Compensation [Line Items]
Expected volatility	72.50%	69.70%
Expected term (in years)	3 years 3 months 18 days	3 years 3 months 18 days

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details 1) - Employee Stock Option	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of Options
Number of options outstanding, balance beginning (in shares) | shares	4,299,810
Number of options issued (in shares) | shares	735,785
Number of options exercised (in shares) | shares	(236,000)
Number of options forfeited (in shares) | shares	(404,251)
Number of options expired (in shares) | shares	0
Number of options outstanding, balance ending (in shares) | shares	4,395,344
Number of options exercisable (in shares) | shares	3,247,214
Weighted Average Exercise Price
Shares outstanding exercise price, balance beginning (in dollars per share) | $ / shares	$ 5.09
Issued, exercise price (in dollars per share) | $ / shares	3.35
Exercised, exercise price (in dollars per share) | $ / shares	1.04
Forfeited, exercise price (in dollars per share) | $ / shares	7.71
Expired, exercise price (in dollars per share) | $ / shares	0
Shares outstanding exercise price, balance ending (in dollars per share) | $ / shares	4.78
Exercisable, exercise price (in dollars per share) | $ / shares	$ 4.74

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details 2)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options outstanding (in shares) | shares	4,395,344
Weighted average exercise price (in dollars per share)	$ 4.78
Weighted average remaining contractual life	6 years 1 month 13 days
Stock options exercisable (in shares) | shares	3,247,214
Weighted average exercise price (in dollars per share)	$ 4.74
$0.55 - $1.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	0.79
Range of exercise prices (in dollars per share)	$ 1.50
Stock options outstanding (in shares) | shares	1,510,000
Weighted average exercise price (in dollars per share)	$ 1.06
Weighted average remaining contractual life	3 years 4 months 17 days
Stock options exercisable (in shares) | shares	1,510,000
Weighted average exercise price (in dollars per share)	$ 1.06
$1.51 - $5.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	1.51
Range of exercise prices (in dollars per share)	$ 5.50
Stock options outstanding (in shares) | shares	898,207
Weighted average exercise price (in dollars per share)	$ 3.22
Weighted average remaining contractual life	8 years 4 months 6 days
Stock options exercisable (in shares) | shares	196,666
Weighted average exercise price (in dollars per share)	$ 2.72
$5.51 - $10.67
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	5.51
Range of exercise prices (in dollars per share)	$ 10.67
Stock options outstanding (in shares) | shares	1,987,137
Weighted average exercise price (in dollars per share)	$ 8.31
Weighted average remaining contractual life	7 years 2 months 15 days
Stock options exercisable (in shares) | shares	1,540,548
Weighted average exercise price (in dollars per share)	$ 8.60

Stock-Based Compensation (Det_5

Stock-Based Compensation (Details 3) - Restricted Stock Units (RSUs)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of RSUs
Non-vested balance at beginning of period (in shares) | shares	188,629
Shares granted (in shares) | shares	122,949
Shares vested (in shares) | shares	(101,607)
Shares forfeited (in shares) | shares	(26,047)
Non-vested balance at end of period (in shares) | shares	183,924
Weighted Average Exercise Price
Weighted average exercise price, non-vested balance beginning (in dollars per share) | $ / shares	$ 8.27
Shares granted - weighted average exercise price (in dollars per share) | $ / shares	3.36
Shares vested - weighted average exercise price (in dollars per share) | $ / shares	9.07
Shares forfeited - weighted average exercise price (in dollars per share) | $ / shares	5.76
Weighted average exercise price, non-vested balance ending (in dollars per share) | $ / shares	$ 4.90

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Income Tax Examination [Line Items]
Income tax (benefit) expense	$ (137)	$ 24	$ (90)	$ 130
Effective income tax rate reconciliation, percent	3.40%	0.30%	0.40%	1.50%
Foreign income tax expense (benefit)	$ 100		$ 100
Remeasurement at new rate, percent					21.00%
Operating loss carryforwards					$ 41,700
Not Subject to Limitations | Subsequent To Change Date In 2010
Income Tax Examination [Line Items]
Operating loss carryforwards					23,100
Subject to Limitations | Minimum
Income Tax Examination [Line Items]
Operating loss carryforwards					1,000
Subject to Limitations | Maximum
Income Tax Examination [Line Items]
Operating loss carryforwards					2,300
Alternative Minimum Tax Carryover
Income Tax Examination [Line Items]
Credit receivable					$ 100

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Other Income and Expenses [Abstract]
Interest expense	$ 2,335	$ 240
Payroll	1,595	1,580
Professional fees	1,221	546
Inventory and Supplies	1,191	58
Capital expenditures	1,042	1,947
Rebates	343	83
Royalties	613	856	$ 600
Clinical studies	593	596
Medicaid and Medicare	365	1,487
Income Tax	30	58
Other	1,109	650
Accrued expenses	$ 10,437	$ 8,101	$ 12,572

Legal and U.S. Regulatory Pro_2

Legal and U.S. Regulatory Proceedings (Details) $ in Millions	Oct. 20, 2017USD ($)drug	Sep. 30, 2018lawsuitgeneric_manufacturer_defendantdruglegal_action
Loss Contingencies [Line Items]
Number of legal actions | legal_action		3
Anti-Trust Lawsuit
Loss Contingencies [Line Items]
Number of putative class action antitrust lawsuits		12
Loss contingency, number of defendants | generic_manufacturer_defendant		34
Number of drugs involved | drug		29
Stayma
Loss Contingencies [Line Items]
Number of drugs involved | drug	2
Damages sought | $	$ 1.7
Opt Out | Anti-Trust Lawsuit
Loss Contingencies [Line Items]
Number of putative class action antitrust lawsuits		1
Loss contingency, number of defendants		35
Number of drugs involved		30